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The rat ventromedial prefrontal cortex  
in the neural circuitries of depression and sleep 
 
ABSTRACT 
 
Major depressive disorder (MDD) is a debilitating disorder affecting hundreds of millions 
of people worldwide. The etiology of the disease is unknown, and how antidepressant 
medications reverse depression is unclear. However, imaging and postmortem studies of MDD 
patients show abnormalities in several limbic areas of the brain, including the prefrontal cortex. 
The involvement of the ventromedial prefrontal cortex (vmPFC) in depression has been 
particularly intriguing, for this region demonstrates reduced metabolic activity in remission, and 
this reduction is unique to treatment responders. In addition, deep brain stimulation targeting the 
subgenual cingulate cortex in the vmPFC has been shown to be effective in treating ‘treatment-
resistant’ patients. Furthermore, neuroanatomical studies have shown that this region projects to 
many downstream limbic areas implicated to play roles in MDD. I therefore hypothesized that 1) 
the vmPFC may be an important target of antidepressant drugs, and that 2) this region may play a 
role in the generation of depression-associated behaviors. To test the first hypothesis, I 
administered desipramine (DMI), a tricyclic antidepressant, to rats. I found that the rat vmPFC 
was significantly activated by DMI, whereas the dorsomedial PFC (dmPFC) was not. I also 
found that the drug increases neuronal activity in the nucleus accumbens, but this activation was 
dependent on the integrity of the vmPFC. To test the second hypothesis, I induced neuronal 
lesions in the rat dmPFC or vmPFC and subjected the animals to behavioral tests. I found that 
 iv 
while lesions in both areas led to increased REM sleep, only vmPFC-lesioned animals had 
reduced REM latency, increased sleep fragmentation and increased forced swim test immobility. 
Together, these results demonstrate that the vmPFC may be an important region for both 
antidepressant action and the generation of depression-like behaviors. 
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Chapter 1 
 
Introduction to sleep, depression and their  
neural circuitries 
 
 
Sleep deprivation is a growing concern for health, safety and productivity. In the US, a recent 
survey reported that adults sleep forty-five minutes less per night than they claim they need to be 
at their best (1). Long-term sleep loss has been associated with medical issues such as 
cardiovascular disease, diabetes, and certain cancers. In addition, psychiatric disorders such as 
depression are strongly associated with sleep changes and disturbances. Patients with depression 
complain of insomnia (and to a lesser degree, hypersomnia), and demonstrate characteristic 
alterations in rapid eye movement sleep: increased amounts per night, shortened latency to onset, 
and increased density of rapid eye movements (2; 3). In addition, most traditional antidepressant 
medications have been found to suppress rapid eye movement sleep. Despite the long-standing 
evidence of a relationship between sleep and depression, the neural circuitry underlying this 
relationship is unknown. A motivating factor for this dissertation was to unearth clues about the 
neurobiology of this relationship.  
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Sleep and Public Health 
Although chronic sleep deprivation is not center stage among the nation’s public health issues, 
societal awareness of its negative consequences appears to be increasing. U.S. regulatory bodies 
such as the Federal Aviation Association and National Transportation Safety Board (NTSB) have 
promptly responded to incidents related to fatigued air traffic controllers and sleepy drivers, and 
the medical industry frequently debates the issue of extended work hours for residents and 
interns. However, there are few broad regulations that attempt to prevent fatigue-related 
accidents or punish the harmful consequences of them. It can be argued that the passage of 
sweeping laws that address fatigue – as in the case of drunk driving a few decades ago – will be 
an indicator that the public has accepted the notion that fatigue is dangerous.  
An obstacle to achieving this milestone is that there are many aspects of sleep we do not 
understand, including why we (and most organisms) have evolved to sleep. Although it has been 
found to improve learning and memory (4), be associated with immune function (6) and improve  
performance of basic tasks (5), the neurobiological functions that necessitate spending several 
hours of every day sleeping are unknown. Furthermore, the purported variability in sleep need 
(7) makes it difficult to distinguish people who are sleep-deprived from individuals who simply 
may require less sleep. 
Nevertheless, the consequences of sleep deprivation have provided fodder for the 
argument that sleep is necessary for one’s well-being. Randy Gardner, a teenager who 
volunteered to fend off sleep long enough to set a Guinness Record, suffered from short-term 
memory loss, moodiness, paranoia and hallucinations by the end of 264 hours (11 days; 10). 
Interestingly, even much more mundane instances of sleep deprivation have been connected to 
negative health consequences: the onset of daylight savings time, which much of the world 
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endures in the early spring, is associated with an increased incidence of heart attacks compared 
to when daylight savings time ends (12). 
Prospective and retrospective epidemiological studies have demonstrated that sleep 
deprivation and rotating shiftwork schedules, which presumably disrupt circadian rhythmicity 
and result in sleep deprivation, can have long-term negative health consequences. For instance, 
sleep deprivation has been associated with increased blood pressure (8), increased inflammatory 
markers (9) and decreased levels of leptin, an appetite-suppressing hormone (16). In addition, the 
Nurses’ Health Study at Harvard has demonstrated that chronically sleep-deprived women have a 
significantly increased risk of coronary heart disease (11) and diabetes (13; 14), and 15-20 years 
of regular rotating shiftwork is associated with increased risk of developing breast cancer (15) 
and colorectal cancer (17). Although these studies are extremely important and informative, the 
biological bases for these associations are yet to be understood. 
In addition to mental and physical health issues related to sleep deprivation, fatigue can 
lead to serious accidents at work and on the road. A Swedish cross-sectional survey found that a 
worker was 1.89 times more likely to die in a work-related accident if he or she had continuous 
sleep problems during the prior two weeks (23). Medical interns made 35.9% more serious errors 
on a traditional schedule, which required work shifts of 24 hours or more every other shift, 
compared to when on an ‘intervention’ schedule that eliminated long shifts and reduced total 
number of hours worked per week (25). Long work hours, as well as shift work, changes in 
family life, illness, and difficult economic circumstances can contribute to sleepy people getting 
behind the wheel. As a result, sleep-deprived drivers cause an estimated 100,000 car accidents in 
the U.S. each year, and lead to over 1500 deaths (27). In one study, 17 hours of sustained 
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wakefulness was found to be comparable to a blood alcohol level of 0.05% in tests for cognitive 
psychomotor performance (29). 
Sleep deprivation is also believed to have a significant economic impact. It has been 
estimated that $20.5 billion is needed to test and treat every sleep apneic patient in the U.S. (31). 
The cost due to shift workers’ difficulty adjusting to their schedules is estimated to be $60 billion 
(33), and lost productivity due to absenteeism, sleep-related accidents, poor decision-making and 
other sources lost productivity are believed to cost businesses $150 billion annually (35). 
Furthermore, many major disasters have at least partially been attributed to fatigue, which may 
have been prevented by adequate sleep. In 1989, an Exxon Valdez crewmember was exhausted 
when the tanker ran onto rocks in Alaska, leading to 11 million gallons of spilled oil (37). The 
NTSB report on the 1997 Korean Airline crash in Guam noted that the pilot was fatigued, which 
may have led to his making poor decisions (39). More recently, the Bronx bus tragedy (2011) 
that killed 15 and seriously injured seven – including by maiming and decapitation – was 
determined by the NTSB to be a consequence of fatigue and sleep loss (41). An investigation 
determined that the driver had less than 4 hours sleep opportunity in the day leading up to the 
accident. 
Despite the immense impact that lack of sleep has been found to have on public health 
and society, there are substantial gaps in our knowledge of its biology and in particular how it 
can lead to mental and physical illness. Therefore deeper pursuit of understanding the neural 
circuitry of sleep should be closely accompanied by research into how sleep dysfunction affects 
the brain and body. 
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The Basics of Sleep 
Architecture of human sleep 
Sleep can be divided into two parts: rapid eye movement (REM) and non-rapid eye movement 
(NREM). During REM sleep, the eyes display rapid movements back and forth underneath the 
eyelids. Most of the body is atonic (18), and blood pressure, heart rate, and respiration rate 
increase slightly compared to NREM sleep (44; 46; 48; 50). It is considered to be the ‘active’ 
stage of sleep (or ‘paradoxical sleep’) because neural activity is at a level similar to wakefulness 
as displayed on an electroencephalogram (EEG; 27). The REM sleep EEG waveform is 
dominated by theta waves, which are in the 4-7 Hz range (Fig. 1-1). Although REM sleep is most 
often associated with dreaming (53), particularly dreams that are recalled upon awakening, 
dreaming can occur during NREM sleep as well (55).  
NREM sleep is characterized by synchronized EEG waves that have high amplitude and 
are of low frequency. There are three stages of NREM sleep, ranging from light (I) to deep (III) 
(recently changed from four stages; 31). The deepest sleep stage, also known as slow wave sleep, 
is typically dominated by delta waves in the 0.5-4 Hz range (59). During NREM sleep metabolic 
rate and body temperature are lowered (61), and the arousal threshold is elevated (19). However, 
muscle tone is not absent during this state, and parasomnias such as sleepwalking, night terrors 
and bed-wetting occur during NREM sleep (63; 65; 67; 69). A NREM sleep bout typically starts 
in stage I and gradually progresses to the deeper stages. After the first bout of slow wave sleep, 
the individual characteristically goes back through stage II and then I of NREM sleep before first 
entering into REM sleep; this progression then repeats at roughly 90-minute cycle intervals (59). 
The ratio of NREM to REM sleep in each cycle starts relatively high and gradually decreases  
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Figure 1-1. Representative human EEG waves in the different vigilance states: wake (A), 
NREM sleep (B), and REM sleep (C). Abbreviations indicate measurements from: CSM = 
sensorimotor cortex; CES = ectosylvian cortex; HIPP = hippocampus; FRM = mesencephalic 
reticular formation; FRP = pontine reticular formation; EMG = electromyogram; YEUX = eye 
movements; PLETH = plethysmographic index; RESP = respiratory activity. From (71); 
permission not required for use.  
	   7 
through the night and into the morning, such that most REM sleep occurs in the usually morning, 
and one usually wakes up from REM sleep. 
Human sleep changes drastically from birth to adulthood. Newborns sleep for 16-20 
hours a day, which is comprised of several sleep episodes (‘fragmented’ sleep). They enter sleep 
via REM sleep, which cyclically alternates with bouts of NREM sleep (20).  Infants typically 
spend a much larger proportion of their time in the deepest stages of NREM sleep compared to 
adults. As infants progress into childhood, their total sleep amount gradually decreases and 
plateaus at about 10 hours per day at ages 6-7 (20). Sleep also becomes more consolidated, and 
the cycles change so that they start with NREM sleep. By puberty, although sleep characteristics 
change little aside from decreased slow wave sleep (21; 22), the homeostatic regulation of sleep 
appears to shift such that they need more sleep (22; 24). For instance, compared to adult males, 
adolescent males demonstrated greater sleep need across many different lengths of time spent 
awake (24). However, adolescence is also associated with a dramatic decrease in sleep amounts 
due to social influences and earlier school start times (26), suggesting that this segment of the 
population is continuously sleep-deprived (28). By adulthood, the recommended daily sleep 
amount is 7-8 hours (79; 81), although the most recent survey by the National Sleep Foundation 
reported that the average American sleeps less (45). 
 
Neural circuitry of human sleep: Sleep-wake control regions 
For many years, conscious wakefulness via cortical activation was believed to be driven by 
inputs from the thalamus and basal forebrain (30; 32). The thalamus has extensive reciprocal 
connections with the cortex, and is also a major relay structure for sensory inputs to the cortex 
(34). In addition, its firing patterns change between wake and sleep states, similar to cortical 
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EEG activity (88), suggesting that it is important for modulating cortical EEG. Retrograde 
tracing studies showed that the cholinergic lateral dorsal and pedunculopontine tegmental nuclei 
(LDT-PPT) innervate the reticular nucleus of the thalamus and surrounding nuclei (90; 92), and 
unit recordings in vivo revealed that the vast majority of cells in this region were wake- and/or 
REM-active (although it has never been confirmed that the cells that were recorded were 
cholinergic; 53). Therefore, it was proposed that the LDT-PPT—thalamus—cortex pathway was 
important for cortical EEG generation and arousal. However, a few studies have challenged the 
importance of the thalamus for driving cortical wakefulness and EEG activity. For instance, 
stimulation of the vast majority of the thalamus did not induce cortical activation (96), nor did 
thalamic lesions prevent cortical activation (98).  Recently the role of the thalamus in arousal and 
sleep-wake circuitry was re-examined (36). Nearly complete lesions of the thalamus caused no 
significant change in any sleep-wake parameters, including total sleep or wake amounts and EEG 
activity (although long-term lesion effects were not studied). In addition, animals did not show 
any signs of increased sleepiness and had increased cortical cfos (an immediate early gene and 
marker of neuronal activation) expression following a prolonged bout of wakefulness, 
comparable to non-lesioned controls. Therefore, despite its neuroanatomical position as an 
important relay structure, the thalamus may not have a role in promoting wakefulness. 
On the other hand, evidence of the importance of the basal forebrain in arousal has been 
strengthened. Large lesions in the basal forebrain produce a coma-like state (36; 38), including 
failure a continuous low-frequency EEG; there is also no cortical cfos expression despite 
continuous gentle handling.  In addition, injections of glutamate agonists into the basal forebrain 
increase wakefulness (40; 42; 43). Monoaminergic nuclei in the brainstem and the histaminergic 
tuberomammillary nucleus in the hypothalamus send projections to the lateral hypothalamus 
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(LH), which in turn projects to the basal forebrain and cortex (Fig. 1-2). The LH includes the 
sole  population of orexin neurons in the brain, although there are orexin receptors distributed 
throughout the brain (45; 47). The orexinergic neurons are wake-active, and appear to modulate 
the sleep-wake switch as well as the REM-on/off switch (see below). For instance, orexin 
knockout mice exhibit narcolepsy-like behavior with cataplexy and frequent vigilance state 
transitions, albeit normal total sleep and wake amounts (107). Optogenetic stimulation of the 
orexin neurons increases wakefulness (49), as do microdialysis applications of orexin into the 
basal forebrain (110; 112). Together, these results suggest that the LH orexinergic projections 
into the basal forebrain act to promote arousal.  
The noradrenergic locus coeruleus (LC), serotonergic dorsal raphe (DR), dopaminergic 
ventral periaquductral gray (vPAG) and histaminergic tuberomammillary nucleus (TMN) have 
also been found to play roles in arousal. Neurons recorded in the LC were found to be most 
active during wake and least active during REM sleep (114). Infusion of noradrenergic alpha2 
receptor agonists into the LC resulted in sleep (116), whereas ventricular administration of 
noradrenaline caused wakefulness (118). Similarly, in the DR, about half of recorded cells were 
wake-active and 18% were wake and REM-active (120), and extracellular levels of serotonin 
were highest during wake (51; 52). A recent study has addressed the presence of dopaminergic 
wake-promoting cells by combining cfos staining with immunohistochemistry against tyrosine 
hydroxylase (TH), which is found in dopamine-containing neurons in the midbrain (54). About 
half the TH-stained cells in the ventral periaqueductal gray matter (vPAG) were wake active, and 
lesions that selectively depleted the dopaminergic vPAG cells significantly increased sleep 
amounts. Lastly, bilateral lesions in the posterior hypothalamus, including the TMN, 
 
	   10 
 
 
Figure 1-2. Diagram of sleep-wake circuitry. (A) Brainstem nuclei that promote arousal via the 
basal forebrain. (B) The VLPO and MnPO (magenta) promote sleep by inhibiting the arousal 
centers. Aqua: cholinergic projections. Green: monoaminergic and glutamatergic projections. 
Blue: orexinergic projections from the lateral hypothalamus. BF, basal forebrain; LDT, 
laterodorsal tegmentum; PPT, pedunculopontine tegmentum; LC, locus coeruleus; PB, 
parabrachial nucleus; PC, precoeruleus nucleus; DR, dorsal raphe nucleus; vPAG, ventral 
periaqueductal gray; TMN, tuberomammillary nucleus; VLPO, ventrolateral preoptic nucleus; 
MnPO, median preoptic nucleus. From (56); used with permission.  
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significantly increased sleep amounts (126) and extracellular unit recordings showed that 
histaminergic TMN neurons were exclusively wake-active (58). Projections from the LC, DR, 
vlPAG, and TMN to the LH have been confirmed by tracing studies (54; 60). 
Strikingly, it was recently found that combined lesions of the parabrachial and 
precoeruleus nuclei (PB/PC) in the brainstem lead to a coma-like state, producing results very 
similar to complete lesions in the basal forebrain (36). As many cells in the PB/PC project to the 
basal forebrain. these results suggest that an essential wake-promoting pathway originates in the 
PB/PC in the brainstem. In contrast to the interpretation by Moruzzi and Magoun (130) that the 
ascending arousal influence originated in the reticular formation, these studies suggest that the 
electrolytic lesions or electrical stimulation in the paramedian midbrain reticular formation 
probably instead involved the ascending projections from the monoaminergic, cholinergic, and 
PB/PC glutamatergic pathways, which run through this region to the hypothalamus, basal 
forebrain, and cerebral cortex.  
The arousal-promoting system in the brain is complicated and involves many different 
structures. On the contrary, just two regions have been established to promote sleep: the 
ventrolateral preoptic nucleus (VLPO) and the recently reported parafacial zone (PZ). A cfos 
study showed that neurons in the VLPO were highly activated following sleep bouts (62), and 
bilateral lesions led to significant decreases in NREM sleep amounts and delta power (64). 
Lesions encompassing the ‘core cluster’ of the VLPO led to the most sleep changes (64), and 
neuronal tracers showed that this region densely innervates the wake-promoting TMN (62). The 
more scattered cells surrounding the core also innervate the LC and raphe nuclei, although to a 
more moderate degree (134). It has been proposed that most of the VLPO cell population 
contains GABA, and thus has a mutually inhibitory relationship with the arousal regions (66). 
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The PZ was discovered following injection of a retrograde tracer cholera toxin B (CTB) 
from the wake-promoting medial parabrachial nucleus in rats (68). Animals were sacrificed 
under waking or sleeping conditions, and cells in the PZ that were stained for CTB only showed 
cfos expression if they had been asleep. Neuronal lesions of the PZ resulted in significant 
increases in wakefulness, and an experiment using mice that express GFP in vesicular GABA 
transporter (VGAT)-containing cells showed that these sleep-active neurons were primarily 
GABAergic. Lastly, selective knockout of the VGAT cells in the PZ using transgenic mice led to 
increased wake amounts and bout durations, confirming that inhibitory cells in the PZ were the 
key subpopulation that promotes sleep. 
 
Neural circuitry of REM sleep 
The REM sleep circuitry has been an area of intense investigation in recent years. A widely 
accepted circuit model proposed by Hobson and McCarley (138) suggested that the brainstem 
cholinergic neurons in the PPT-LDT promote REM sleep, and monoaminergic neurons in the DR 
and LC prevent it. However, this model was challenged by a number of findings. For instance, 
the target monoaminergic site that suppressed REM sleep was unclear, particularly serotonin 
(140). In addition, lesions of the monoaminergic brainstem nuclei had limited effects on REM 
sleep and its characteristic atonia (70; 72; 73). On the other hand, lesions in the SLD had been 
found to prevent REM atonia, causing cats to “act out” their dreams (74; 75). Furthermore, local 
administration of GABA antagonists bicuculline and gabazine into the SLD were found to 
induce REM sleep with very short latency, as did glutamate agonist kainic acid (76). These 
results suggested that the SLD was important in REM sleep generation, and GABA played a role 
in delaying REM onset while glutamate promoted it. The ventrolateral periaqueductal gray-
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lateral pontine tegmentum (vlPAG-LPT) was a candidate ‘REM-off’ control region to the SLD 
because injections of GABA agonist muscimol in this region of the cat led to large increases in 
REM sleep (146). Subsequent studies showed that lesions in the ventrolateral periaqueductal 
gray-lateral pontine tegmentum (vlPAG-LPT) of rats led to an increase in REM sleep, and 
lesions in the sublaterodorsal nucleus-precoeruleus (SLD-PC) significantly decreased REM sleep 
(147). These results indicated that the vlPAG-LPT and SLD-PC were the REM-off and REM-on 
control areas, respectively. Tracing studies showed that these areas project to each other, and that 
many of the inputs from both were GABAergic (147; 148). Therefore, the authors proposed that 
these REM control areas mutually inhibit each other to form a ‘flip-flop switch’. 
These REM control areas are modulated by many nuclei on both sides of the switch. As 
mentioned above, orexinergic neurons are found in the LH, and orexin knockout mice display 
narcolepsy-like behaviors (107). It is believed that the cataplexy that occurs in these animals is 
an incomplete display of REM sleep with atonia, so orexin may be important for controlling 
entry into REM. In addition, LH orexin neurons are relatively quiet during REM sleep (77; 78), 
so their projection to the vlPAG-LPT suggests that they may be assisting in the suppression of 
REM sleep by activating the REM-off region during wake. 
Cells in the extended VLPO (eVLPO) were found to contain GABA and galanin, both 
inhibitory neurotransmitters, and be REM-active (80). This region also sends projections to the 
vlPAG-LPT (82), and VLPO lesions that include this region cause a decrease in REM sleep (64). 
Therefore, the eVLPO appears to block the vlPAG-LPT to allow REM sleep to occur. 
The LDT-PPT, LC and DR that are important in arousal also appear to play roles in REM 
control. In the LDT-PPT, 97% of cells recorded in this region were found to be REM-active or 
REM- and wake-active (149). However, none of these studies identified the chemical phenotype  
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of the neurons being recorded, which will be very important in understanding their role in sleep. 
Although lesions of these regions do not change REM sleep amounts (147), injecting 
acetylcholine into the brainstem induces a REM-like state (150; 151). Although the circuitry by 
which the LDT-PPT modulates the REM switch is unclear, Lu and colleagues have proposed that 
the cholinergic and monoaminergic neurons modulate the activity in the vlPAG/LPT-SLD flip-
flop switch. 
Neurons in the LC are REM-off active (114). Again, although lesions here did not change 
the amount of REM sleep, they did cause a reduction in ponto-geniculo-occipital (PGO) spikes 
(70), which are most prominent immediately before REM sleep onset in cats. Compared to wake 
and NREM sleep, extracellular GABA concentrations were found to be higher in this region 
during REM sleep (84). Together, these data suggest that LC neurons assist the suppression of 
REM sleep, and are inhibited by GABA during REM sleep. 
Serotoninergic neurons of the DR also may be REM suppressant. Microinjections of 
muscimol, a GABA agonist, into the DR lead to 67% increase in REM sleep, whereas injection 
of picrotoxin (a GABAA receptor antagonist) abolishes REM sleep (85).  
REM sleep is characterized by muscle atonia and hippocampal theta waves in rodents. 
Lesions of the ventral SLD caused REM sleep to occur without atonia, suggesting that the 
mechanism for atonia depends on this nucleus (147). Initially it was believed that atonia was 
induced by inhibitory projections from the ventromedial medulla, as tracing studies in cats under 
identified glycinergic neurons that expressed cfos during carbachol-induced REM sleep (152).  
However, lesions in this area of the rat did not affect REM atonia (147). It was subsequently 
shown that the SLD may directly project to cells in the spinal cord, as a retrograde tracer 
injection into the ventral horn of the spinal cord labeled cells in the SLD (147). Furthermore, 
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nearly all the labeled cells contained VGLUT2 mRNA, which is the transcript for a glutamate 
transporter protein. Anterograde tracer injection into the SLD demonstrated that most spinal cord 
neurons that the SLD neurons appose are inhibitory interneurons. Together, these results suggest 
that SLD neurons may inhibit muscle tone during REM sleep by excitation of interneurons that 
in turn suppress motor neurons. 
 It has been suggested that hippocampal theta rhythms are driven by GABAergic neurons 
in the medial septum (MS) (153). A retrograde tracer injection into the MS demonstrated labeled 
cells in the PC, and most of these cells are glutamatergic (147). Furthermore, ibotenic acid 
lesions in the PC abolished theta rhythms during sleep. Therefore, these results suggest that the 
PC may drive the signature theta rhythms of REM sleep. 
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Major Depressive Disorder and Sleep 
There is a plethora of evidence that sleep is linked to psychiatric disorders. For instance, patients 
suffering from anxiety disorder report an increased latency to sleep, decreased sleep efficiency 
and decreased total sleep (154). Schizophrenic patients report difficulty initiating and 
maintaining sleep, daytime fatigue, and reduced REM latency (155). Major depressive disorder, 
one of the most common mental disorders in the U.S. (156), also has strong associations with 
sleep changes. The majority of those suffering from depression complain of insomnia (86; 87), 
and they also demonstrate reduced slow wave sleep (89) and shortened REM latency (91). 
However, the biology underlying the relationship between affect and sleep changes is unclear. I 
was interested in investigating this relationship, which I report on in this dissertation. 
Major depressive disorder (MDD) is a debilitating disease characterized by a loss of 
interest in pleasurable things and a persistently depressed mood. MDD is primarily characterized 
as a disease of first-world countries: by one account, of the estimated 121 million that suffer 
from the disease worldwide, 14.8 million are in the U.S. (157). In addition, the lifetime 
prevalence of depression in the U.S. is 17% (93; 157). A patient is diagnosed to have MDD when 
he or she experiences depressed mood, loss of interest, and has at least three of the following 
additional symptoms for a minimum of two weeks: appetite/weight disturbance, sleep 
disturbance, psychomotor change, loss of energy, feelings of worthlessness/guilt, concentration 
difficulties/indecisiveness, or thoughts of death/suicide (158; 159). This symptom-based 
definition is a reflection of the difficulty scientists have faced in identifying a specific cause of 
depression. Furthermore, the biological basis of each of these symptoms is not well understood. 
Although epidemiologic studies show that 40-50% of the risk of depression is genetic (93; 95), 
non-genetic factors such as stress, emotional trauma, and nervous system abnormalities also 
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likely underlie the pathophysiology of MDD (160).  
 
Sleep alterations in depression 
As mentioned, patients with MDD show substantial alterations in their sleep architecture. 
Approximately 80% of depressed patients complain of insomnia, while 15-35% demonstrate 
hypersomnia (86; 161). Although abnormalities in both NREM and REM sleep have been 
reported, the latter are more pronounced and consistent. Typically patients experience increased 
REM sleep, shortened REM sleep latency (the interval of time between sleep onset and REM 
onset), and increased REM density (2; 3; 97; 99). Notably, these changes are observed in both 
insomniac and hypersomniac patients (100), so the REM sleep changes are unlikely to be related 
to increased sleep pressure following sleep loss. 
REM sleep changes are also observed in animals exposed tochronic stress that are 
believed to exhibit behaviors related to depression. For example, two weeks of chronic mild 
stress led to increased REM sleep (101), and 15 days of inescapable footshocks  resulted in 
reduced REM sleep latency as well as increased REM sleep (102). Flinders Sensitive Line rats, a 
line bred to be hypersensitive to cholinergic agonists (which is a trait observed in depressed 
humans), and prenatally stressed rats also show increased REM sleep (132; 162). On the other 
hand, most traditional antidepressant drugs have been found to suppress REM sleep, in humans 
as well as in animals (2; 103–106), although the mechanism of this suppression is unknown. 
Altogether, these data suggest that there is an interrelationship between REM sleep and 
depression-like behaviors.  
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Cortical involvement in depression: Human literature 
Imaging studies have shown that depressed patients exhibit abnormal activity in certain brain 
regions compared to healthy subjects, including the amygdala, medial thalamus, and regions of 
the prefrontal cortex. Even in healthy subjects, clinical studies suggest that limbic structures, 
including subregions of the prefrontal cortex, play a role in affect regulation (158). When 
volunteers were asked to think of a sad memory during fMRI imaging, blood flow increased to 
the lateral orbital and ventrolateral PFC (vlPFC; 122). Another study found that happy memories 
caused a decrease in blood flow to the ventromedial PFC, while sad memories caused an increase 
(surprisingly, MDD patients demonstrated the opposite pattern; 123). Emotion-evoking 
photographs, either positive or negative, caused an increase in activity in the ventral and dorsal 
medial PFC and decrease in the lateral PFC compared to neutral photographs (164). The vlPFC 
was also found to be involved in active judgment of information that is held in cortical 
association regions, suggesting that the decision-making process of how to react to emotional 
thoughts may partially be made here (165). 
The ventromedial PFC has particularly been receiving increased attention in human 
studies of depression in recent years. This region includes the rostral anterior cingulate (rACC, 
BA24), prelimbic (BA32) and subgenual cingulate cortices (SGC, BA25). A study showed that 
the rACC was hypometabolic in depressed patients overall, but those that responded to 
antidepressant treatment were actually distinctly hypermetabolic at baseline (109). On the other 
hand, the SGC of depressed patients displayed increased activity (111; 113) and decreased gray 
matter volume (111; 115; 117; 119). Six weeks of antidepressant treatment reduced blood flow 
in this region, and further analysis demonstrated that this reduction was specific to those that 
responded to treatment (121). These findings suggest that receptiveness to depression alleviation 
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via antidepressants may have a neurobiological basis (via the rACC), that the SGC may be a 
state marker of depression, and that generally the ventromedial PFC may be involved in the 
antidepressant response. 
Deep brain stimulation (DBS) originally developed to treat Parkinson’s Disease (166–
168), was recently attempted in depressed patients for the first time (122). The electrode was 
placed just outside the SGC. Although the six patients had been labeled ‘treatment-resistant’, 
failing to respond to multiple modes of antidepressant therapy, three of them achieved remission 
or near-remission and one additional patient continued to experience an antidepressant response 
at the conclusion of the six-month study. A second study had similar results after targeting the 
same area in twenty patients (123). These patients also displayed decreased blood flow in the 
SGC after six months (122; 123), so it was suspected that DBS had local inhibitory properties. 
However, activity changes were observed in many brain areas that are downstream of the DBS 
target region in both MDD (122–124) and PD patients (125; 127; 128), suggesting that changes 
in neural network dynamics may be essential.  
 Indeed, tracing studies in Macaca fuscata monkeys found that the ventromedial 
prefrontal cortex in primates projects to many important limbic regions believed to participate in 
the depression circuitry, including the nucleus accumbens core and shell regions, amygdala, 
insular cortex, and septal nuclei (169). This region of the brain therefore appears positioned to 
influence activity in the limbic circuitry and play an important role in mood regulation.  
 
The rodent as an animal model of depression 
Although studying major depressive disorder exclusively in humans would be ideal, intrinsic 
variability among subjects and limitations in methods would make it difficult to significantly 
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advance our knowledge. For these reasons, animal models of depression are useful and 
necessary. Rodents, particularly rats, are good animal models because of their limited variability 
and uniform genetic background. We also have extensive knowledge of their neuroanatomy and 
neurocircuitry, including on regions of the brain believed to control emotion and reward. Based 
on neuroanatomical and functional studies, it has been accepted that rats possess a prefrontal 
cortex that shares many similarities with primate prefrontal cortex (170; 171). Although there has 
been some discrepancy about which specific human PFC subregion is homologous to the rat 
medial prefrontal cortex, a careful tracing study of the PFC of non-human primates revealed that 
BA25 and 32 in primates have very similar efferent projections to the rat vmPFC (169; 172). 
Therefore, the rat vmPFC is an excellent area to investigate neuroanatomical and behavioral 
questions regarding MDD, given the believed importance of the vmPFC in human depression 
(111; 121; 113; 122). 
Although it is challenging to observe and measure depression in animals, several tests  
have been established in rodent depression research. In rats and mice perhaps the most common 
is the forced swim test (FST), also known as the Porsolt swim test (129). In this two-day test, a 
rat is placed in a cylinder of water of standard size and temperature for fifteen minutes the first 
day and five minutes the second day. The outcome measure is the amount of time an animal 
spends immobile during the second test session. A similar version is performed with mice, but 
with only one five-minute session (131). The FST was originally established as a model to detect 
antidepressant efficacy, and its predictive validity has been demonstrated from the wide range of 
antidepressants it detects as well as the non-antidepressants (such as anxiolytics) it does not 
(173). However, it is also used to demonstrate depression-like behaviors in animals that have not 
received antidepressant drugs (132; 133; 135–137). Although in this capacity it is acknowledged 
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that it has limited face validity, it is generally accepted that immobility is a quantifiable behavior 
that may be associated with depression (174). First, decreased immobility during the FST is 
observed following animal models that demonstrate aspects of depression, such as chronic mild 
stress (animals are exposed to a variety of stressors such as light during the night, food and/or 
water deprivation, cage tilt, etc. daily for weeks) (175; 176) and social defeat (animal is 
subjected to weeks of daily stress due to presence of a dominant animal) (139; 141). Second, the 
first swim session appears to change something in the animal, as it has been shown that animals 
that experience inescapable (but not escapable) water immersion are unable to learn a shock 
avoidance task compared to animals that could escape (177), suggesting that they are more 
vulnerable to feeling helplessness. Lastly, there is evidence that FST immobility is associated 
with a specific gene cluster. A group of researchers crossed two lines of mice that demonstrated 
the greatest and least amounts of immobility in the FST and tail suspension test (TST), and 
searched for genes that may inform the results in each (178). A whole genome quantitative trait 
locus analysis determined that a locus on mouse chromosome 11 was significantly associated 
with both FST and TST results, and candidate gene analysis pointed to a gene cluster that 
encodes GABAA receptor subunits alpha-1 and alpha-6. They found that between the two 
progenitor lines, the GABAA alpha-1 gene was expressed significantly more in one line, and in 
the GABAA alpha-6 subunit there was a single amino acid difference. A clinical study showed 
that polymorphisms on the human syntenic region of these genes was associated with mood 
disorders in female patients, compared to age-matched controls (179). In summary, although the 
FST is not an ideal rodent test in depression studies, there is evidence that it is a useful tool for 
studying behaviors that may be associated with depression.  
 
	   22 
Cortical involvement in depression: Rodent literature 
There is mounting evidence that the rat mPFC may be involved in the regulation of stress and 
emotion. Chronic (daily for three weeks) and even one week of mild stress led to changes in 
dendritic morphology in the mPFC (142–144). Lesions of the rat ACC led to increased time 
spent immobile during the FST (180), and glial cell loss by astrocyte-specific toxin L-alpha-
aminoapidic acid has been shown to produce increased immobility in the FST and decreased 
sucrose preference in rats (136). Since treatment-resistant depressed patients responded to deep 
brain stimulation in the SGC (122), the rodent vmPFC has been targeted for deep brain (135) and 
optogenetic stimulation (145) in recent studies. Deep brain stimulation in the rat during a FST 
protocol significantly decreased immobility compared to non-stimulated controls, suggesting an 
antidepressant effect. Optogenetic stimulation in the vmPFC of mice that displayed susceptibility 
to social defeat stress improved performance in a social interaction test and the sucrose 
preference test. In addition, the defeated mice had reduced expression of immediate early genes 
zif268, cfos and arc (145). Altogether, these studies suggest that reduced activity in the rodent 
vmPFC seems to be linked to depression-associated behaviors, whereas increased activity may 
be antidepressant. 
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Specific Aims 
Studies of depressed patients demonstrate that the ventromedial prefrontal cortex displays 
abnormal metabolic activity and blood flow, which normalize upon successful treatment and/or 
remission. In addition, treatment responders display unique changes in imaging studies compared 
to nonresponders in this area. Lastly, recent evidence that treatment-resistant patients can 
successfully be treated with deep brain stimulation targeting the subgenual cingulate cortex 
suggests that this area may also be an important target for antidepressant therapies. For my 
dissertation work, I therefore hypothesized that the ventromedial prefrontal cortex may be a key 
target in antidepressant treatment as well as play a role in the generation of depressive behaviors. 
 
Aim 1: Do antidepressant drugs target the ventromedial prefrontal cortex? 
To study whether antidepressant drugs may be acting on or through the ventromedial prefrontal 
cortex, we administered desipramine (tricyclic antidepressant), fluoxetine (elective serotonin 
reuptake inhibitor), and ketamine (NMDA antagonist) to rats. We then examined the whole brain 
for regions that were selectively activated by each of these three drugs. Using tracing data in the 
literature as well as our own studies, we further asked what pathways appear to be important for 
the action of desipramine. 
 
Aim 2: Does the ventromedial prefrontal cortex play a role in generating depressive 
behaviors, including sleep modulation? 
Next, to understand the role the ventromedial PFC may have in giving rise to depression, we 
used ibotenic acid to induce neuronal lesions in the subregions of the rat medial prefrontal 
cortex: the dorsal mPFC (anterior cingulate) and ventral mPFC (prelimbic and infralimbic 
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cortices). We then recorded the animals’ sleep-wake behavior and administered forced swim test, 
which are both measures of depressed state. Upon finding that lesions in the medial prefrontal 
cortex lead to REM sleep changes, we used anterograde and retrograde tracers to investigate 
possible neural pathways of sleep modulation. 
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Chapter 2 
 
Antidepressant drugs selectively activate the rat 
ventromedial prefrontal cortex 
 
ABSTRACT 
 
Research on traditional antidepressant drugs led to the monoamine hypothesis, which postulated 
that major depressive disorder (MDD) is a consequence of a chemical imbalance in the brain. 
However, this hypothesis is now considered unlikely and the pursuit of understanding the mood-
elevating effects of antidepressants continues. The prefrontal cortex (PFC) of depressed patients 
displays abnormal activity, such as increased blood flow in the subgenual and ventrolateral PFC, 
which normalizes in patients who are asymptomatic or in remission. Furthermore, the subgenual 
and orbitofrontal PFC display decreased volume sizes that may be due to reductions in cell 
numbers, suggesting that dysfunction in these regions may be important for MDD etiology. We 
therefore hypothesized that antidepressants may target the PFC to reverse depression. We used 
the rat as an animal model to study the neural targets of desipramine, a tricyclic antidepressant. 
We found that cfos expression selectively increased in the ventromedial PFC following drug 
treatment, and increased expression only occurred in layers V-VI. This pattern was replicated 
following administration of fluoxetine, a selective serotonin reuptake inhibitor, and ketamine, an 
NMDA-antagonist recently found to have antidepressant properties. In addition, of the 
downstream limbic targets of the vmPFC only the NAc was activated by desipramine, and this 
activation was lost upon vmPFC neuronal lesions. These results suggest that the vmPFC may be 
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an essential target of antidepressant drugs, and vmPFC projections to the NAc may be a key 
circuit regulating antidepressant action. 
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Introduction 
Monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), selective serotonin 
reuptake inhibitors (SSRIs) and other classes of drugs have been prescribed to treat Major 
Depressive Disorder (MDD) over the past several decades. Limited knowledge of how these 
drugs worked gave rise to the monoamine hypothesis of depression, which postulated that a 
neurochemical imbalance in the brain contributed to the etiology of MDD (1). While this theory 
is currently considered overly simplistic, we still lack a complete understanding of the mood-
elevating mechanism of these drugs. Greater insight into how these medications work may shed 
light on the etiology of MDD. 
Antidepressant medications are taken systemically yet they have different effects on 
different regions of the brain (2). The changes observed before and after treatment in the 
prefrontal cortex (PFC) of MDD are particularly intriguing. For instance, depressed patients 
demonstrate increased activity in the subgenual and ventrolateral PFC (3; 4) and increased 
activity in the amygdala (4). The PFC activity changes are reversed in patients in remission (4; 
5), and these changes may be essential for a positive response to antidepressant drugs. 
Responders to the SSRI fluoxetine after six weeks of treatment demonstrated changes in cerebral 
blood flow compared to non-responders, including decreases in the subgenual cingulate and 
increases in the dorsal PFC (5). In addition, volume decreases are observed in certain brain 
regions of depressed patients, and are most consistently reported in the orbitofrontal and 
subgenual PFC (4; 6–8). Post-mortem analyses of the brains of depressed patients demonstrated 
that both these regions have significantly reduced number of glial cells but do not show changes 
in neuronal cell numbers compared to healthy controls (8; 9), providing a possible explanation 
for the volume reduction. This notion is supported by animal work that has shown that chronic 
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restraint stress leads to dendritic atrophy, including reduced length and total branch numbers of 
apical dendrites in pyramidal cells of the rat mPFC (10–12).  
Furthermore, there is mounting evidence that antidepressant treatment is associated with 
increased neuroplasticity and changes in cell morphology (13–17).  For instance, chronic 
imipramine (a TCA) treatment resulted in increased levels of three plasticity-associated proteins 
in the rat PFC (15), and even a single dose of the MAOI iproniazid significantly increased the 
area of dendritic profiles (18). Therefore, the PFC may be an important region for both the 
underlying pathophysiology of MDD as well as the mood-alleviating effect of antidepressants.  
Ketamine, an NMDA-antagonist typically used as an anesthetic agent, has recently been 
found to rapidly alleviate depression in humans and demonstrate antidepressant-like properties in 
rodents (19–22). Acute doses injected in rats have been found to increase synaptic spine density 
in the mPFC (22). In addition, its antidepressant-like effects may be dependent on the PFC, as 
infusion of rapamycin – which blocks an important signaling pathway involved in cell growth 
and survival – into the rat mPFC via cannulae prevents synaptogenesis and the antidepressant-
like response of ketamine (22).  
Despite the evidence for prefrontal cortical involvement in depression and its role in 
responding to antidepressants and ketamine, few studies have been performed that investigate the 
effect these drugs have on the prefrontal cortical-limbic neural circuitry. The rat mPFC is 
believed to have similar basic neuroanatomical traits as the human PFC (23–25), and therefore 
serves as an appropriate animal model. In particular, the rat vmPFC projects to many limbic 
areas implicated in control of emotion, such as the lateral septum, basolateral amygdala, insular 
cortex, and nucleus accumbens. These studies suggest that the mPFC may play a key role in both 
depression and in the therapeutic effects of antidepressant medications. To test this hypothesis, I 
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acutely administered desipramine, a TCA, fluoxetine, an SSRI or ketamine into healthy rats and 
examined patterns of neuronal activity via the immediate early gene transcript, cfos, in the mPFC 
and its downstream limbic targets. 
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Methods 
Animals 
All animals used were pathogen-free adult male Sprague-Dawley rats (350-400g) purchased 
from Taconic (Hudson, NY). They were housed in individual cages in rat-specific holding rooms 
controlled for temperature (22±1°C) and humidity. Food and water were available ad libitum, 
and lights were automatically switched on and off according to a 12:12 L:D cycle (lights on 
8:00am – 8:00pm). The animals were cared for in accordance with National Institutes of Health 
standards, and all procedures were pre-approved by the Beth Israel Deaconess Medical Center 
Institutional Animal Care and Use Committee.  
 
Animal lesion surgery 
Prior to surgery, animals were anesthetized with ketamine-xylazine (i.p., 800 mg/kg ketamine, 
80 mg/kg xylazine, Med-Vet, Mettawa, IL) and then placed on a stereotaxic frame so that their 
head was fixed. Injections of ibotenic acid (IBO, Tocris, Ellisville, MO), 0.9% saline (Med-Vet, 
Mettawa, IL) or CTB (List Biological, Campbell, CA) were administered directly into the brain 
using a fine glass pipette (1 mm glass stock, tapering slowly to a 10-20um tip) connected to an 
air compression system. A series of 20-40psi puffs of air were used to deliver the compounds 
into and with the following coordinates (Paxinos and Watson, 2005) and volumes: vmPFC: 
AP+3.0mm  DV-3.4mm RL+/-0.6mm, 66-99nL 5% IBO, 16.5nL 1.0% CTB; NAc: AP+2.0mm  
DV-6.8mm  RL+/-1.0mm, 23.1nL 1% CTB. Incisions were closed with wound clips. Upon 
completion of the procedure, the animal was given a subcutaneous injection of analgesic 
meloxicam (1.0 mg/kg, Med-Vet, Mettawa, IL) and allowed to recover on a warm plate until 
awakened from anesthesia.  
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Forced swim test 
The forced swim test procedure was conducted as described in Detke et al. (26) and Castagné et 
al. (27). The test was conducted over two days using acrylic cylinders (20cm x 40cm; Northeast 
Plastics, Philadelphia, PA) that were filled 30 cm with 25°C water. On the first day, animals 
were placed in the cylinder for 15 min while being video recorded using a computer running 
Ethovision (Noldus, Leesburg, VA). The animals were subsequently removed and gently handled 
and dried before being returned to their cages. On the second day, the swim test was repeated for 
5 min. All animals were habituated to the room at 12:00 and the swim tests were completed 
between 13:00 and 15:00 to limit any circadian influences. Injections of drug or saline were 
administered three times: immediately following the first swim session, 4 hours prior to the 
second session, and 1 hour prior to the second session. Total amounts of immobility during the 5-
min test session were scored using Ethovision and parameters validated for rats (28) (sampling 
rate 5 Hz; immobility threshold 11.5%). It has been shown that lesions in the rat mPFC do not 
impair locomotor activity (29), and we confirmed during the day 1 swim session that neither 
experimental group displayed movement deficits. FST immobility between lesion groups 
receiving saline or DMI were analyzed using unpaired t-test, using a significance threshold 
p<0.05.  
 
Antidepressant Drug Treatments 
To study neuronal activation patterns upon acute drug treatment, animals were placed in isolated 
chambers for at least two days. We chose these conditions (including performing injections in 
the morning) to maximize the likelihood that the animals would fall sleep following the 
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injection. At 10am after habituation, animals were gently handled and weighed. At 10am the 
following day, animals were injected i.p. with desipramine hydrochloride (10 mg/kg in saline, 
Sigma, St. Louis, MO), fluoxetine hydrochloride (Sigma, St. Louis, MO; 20 mg/kg in saline) 
ketamine (10 mg/kg in saline, Med-Vet, Mettawa, IL) or sterile saline (0.9%, Fisher Scientific, 
Pittsburgh, PA). The animals were then placed back in their cages and in their chambers for two 
hours, after which they were sacrificed via perfusion and fixation (see below) and their brains 
stained for cfos immunohistochemistry. 
 
Perfusion and fixation 
Animals were anesthetized with 7% chloral hydrate (i.p. 500 mg/kg, Sigma, St. Louis, MO). The 
body cavity was opened using surgical scissors and a 16G needle was inserted into the left 
ventricle of the heart. The top of the right atrium was cut to allow blood to be drained. About 100 
mL of saline was flushed through the vascular system using an intravenous line, followed by 
500mL of 10% buffered formalin (Fisher Scientific, Pittsburgh, PA). Upon fixation of the tissue 
the brain was removed from the skull and stored in 10% formalin for 4-5 hours. The brains were 
then moved to 20% sucrose and 0.02% azide solution overnight. 
 
 
 
Histology and Immunohistochemistry 
Brains were sliced into four series of 40um sections using a freezing microtome. The sections 
were stored in PBS-0.02% azide in 20°C.  
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Immunohistochemical staining was completed as follows: tissue sections were rinsed in 
PBS three times, 3-5 min each. They were then incubated for 30 min in 0.3% H2O2 (Sigma, St. 
Louis, MO) in PBT (phosphate buffer with Triton X-100; Sigma, St. Louis, MO) to oxidize any 
remaining blood. The sections were again rinsed in PBS and then incubated in primary antibody 
diluted in PBT-Azide for 1-2 nights, depending on the antibody (cfos Ab-5, PC38, rabbit 
polyclonal, 1:30,000, Calbiochem, Billerica, MA; Chemicon, Billerica, MA; CTB, 127H4810, 
goat polyclonal, 1:50,000, Sigma, St. Louis, MO). Tissue were then rinsed in PBS three times, 
and incubated in secondary antibody (1:1000, biotin SP-conjugated against appropriate species 
IgG, Jackson ImmunoResearch Laboratories, West Grove, PA) for 60-90 min. Sections were 
again rinsed in PBS and placed in ABC solution (1:1000 each Vectastain solutions A and B, 
Vector Laboratories, Burlingame, CA) for 60-90 min. Sections were rinsed in PBS and stained 
for 5 min in a solution consisting of: 1% DAB, 0.3% H2O2 (and 0.01% Ni, 0.005% CoCl2 if 
desired a black stain). Tissue were then rinsed and mounted on microscope slides in gelatin. 
Sections were Nissl stained by placing microscope slides of mounted tissue in ddH2O for 
5 min, followed by 10-30 sec in 0.1% thionin staining solution (t Sigma, St. Louis, MO). The 
slides were dehydrated step-wise by incubating in 50% EtOH, 70% EtOH, 95% EtOH, and 100% 
EtOH for 2 min each. Slides were then placed in xylene for several hours before covering with 
glass coverslips.  
 
Cell Counting 
All cfos-stained cells were counted at 25x magnification. For the ACC and PLC, three sections 
were counted and summed (rostral: Bregma +4.2mm, middle: Bregma +3.2mm, caudal: Bregma 
+2.5mm) and for the ILC two sections were counted (middle and caudal). Counting boxes used 
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were 400µm x 400µm. For the ACC, two boxes were placed corner to corner at the dorsomedial 
edge of the ACC, and for the ventral regions one box each was placed in the deep and superficial 
layers. Three sections were counted of the rostral NAc (Bregma +2.0 to +2.5mm): 400µm x 
400µm counting boxes were placed immediately ventral to the anterior commissure (core) and 
lateral to the core along the medial edge of the NAc (shell). Three sections in the basolateral 
amygdala (Bregma -3.0mm to -3.3mm) were counted; two sections of the lateral septum 
(Bregma +1.7mm to +1.5mm) with counting box aligned to lateral ventricle; and two sections of 
the insular cortex (Bregma +3.0mm and +2.5mm) with counting box placed along the cortical 
edge. Counting box used for these structures was also 400µm x 400µm. The anterior-posterior 
levels were chosen based on projection patterns of the vmPFC (30). All cell counting data were 
corrected using Abercrombie’s correction (31). 
 
Statistical Analyses 
All of the cell counting data were analyzed using the unpaired t-test, except in the case of the 
nucleus accumbens cfos comparisons in animals with and without vmPFC lesions when a 2-way 
ANOVA was used. In the comparison between fluoxetine, ketamine and saline injections, p-
values were adjusted with Bonferroni’s adjustment. p<0.05 was used as the threshold for 
significance. 
 
  
	   56 
Results 
Desipramine activates deep layers of the rat vmPFC 
To investigate whether antidepressant drugs may be targeting the prefrontal cortex, we 
administered desipramine (DMI) to adult male Sprague-Dawley rats (Fig. 2-1). The dose used 
(10 mg/kg) has been shown to be effective in the forced swim test, a rodent model of depression 
originally validated to demonstrate antidepressant efficacy (26; 32; 33).  Saline was injected into 
animals under identical conditions as a control. Both groups showed sleeping postures in the 
interval between injection and perfusion, which was verified by EEG/EMG recording in two rats 
that received DMI (Fig. 2-2).  REM sleep was completely suppressed by the drug for several 
hours, but NREM sleep and wakefulness parameters were not affected). In addition, animals of 
both groups showed a cfos activation pattern typical of sleeping animals, including high cfos 
expression in the sleep-active neurons of the ventrolateral preoptic nucleus, and low expression 
in the arousal regions such as the tuberomammillary nuclus (Fig. 2-3). Compared to controls, 
animals given DMI exhibited a significant increase in cfos expression in the ventral mPFC (i.e., 
the prelimbic and infralimbic cortices; average cell counts, saline v. DMI: 54.1±13.5 v. 
120.1±22.4; t(8)=2.52 p=0.036), whereas this was not seen in the dorsal mPFC (anterior 
cingulate cortex; saline v. DMI: 4.4±1.8 v. 10.5±3.5; t(8)=1.54, p>0.05; Fig. 2-4A). The 
delineation of the mPFC was based on Paxinos and Watson’s Rat Atlas (34) and 
cytoarchitectural characteristics as described in Hurley et al. (35). 
As the mPFC consists of five cortical cell layers (I,II,III,V,VI), we divided the vmPFC 
into superficial (I-III) and deep layers (V-VI) and counted them separately to observe any  
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Figure 2-1. Animals were injected with saline (A-C) or DMI (D-F) (i.p., 10 mg/kg) at 10:00am 
and sacrificed two hours later. Cells in the mPFC stained with cfos are indicated by red dots in 
the anterior cingulate (A and D), prelimbic (B and E), and infralimbic (C and F) cortices. The 
prelimbic and infralimbic cortices, collectively called the vmPFC below, show a dramatic 
increase in cfos expression following drug administration whereas the anterior cingulate 
(dmPFC) is relatively quiet. Scale bar in F indicates 0.25mm. 
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Figure 2-2. Sleep-wake analysis of animals administered saline or desipramine on consecutive 
days (n=4). A, B, and C show hourly wake, REM sleep, and NREM sleep percentages over 24h. 
D, E, and F show vigilance state percentages, bout numbers, and average bout durations during 
the 12h light period. Injections were given at approximately 9:00am.  
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Figure 2-3. cfos expression in the ventrolateral preoptic nucleus (A and C) and 
tuberomammillary nucleus (B and D) following saline (A and B) or desipramine (C and D) 
injections indicate that animals were sleeping during the interval between injection and sacrifice. 
Scale bars indicate 0.5mm.  
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Figure 2-4. A The vmPFC, but not the dmPFC, was significantly activated upon DMI injection 
(i.p. 10 mg/kg, n=5) compared to saline-injected animals (n=5). B Within the vmPFC, there was 
a clear distinction in the number of cfos-stained cells between the deep layers (V-VI) and 
superficial layers (I-III).  
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differentiation in cfos expression. We found that the increase in cfos expression in the vmPFC 
due to DMI was entirely due to the deeper layers (Fig. 2-4B; saline v. DMI, layers V-VI:  
30.5±8.9 v. 81.1±12.1, t(8)=3.37, p=0.0099), whereas the superficial layers were not statistically 
different between DMI and saline (saline v. DMI, layers I-III: 23.6±5.9 v. 38.9±10.8, t(8)=1.25, 
p>0.05). 
 
Fluoxetine and ketamine also selectively activate vmPFC 
To investigate whether pharmacological agents of classes other than TCAs produce similar 
patterns of neuronal activation in the mPFC, we treated animals under the same protocol with 
fluoxetine (FLX, 20 mg/kg) and ketamine (KET, 10 mg/kg; Fig. 2-5). The doses were chosen 
based on their effectiveness in decreasing immobility in the forced swim test (22; 26). We found 
that, like DMI, FLX induced an increase in cfos expression in the vmPFC compared to animals 
that received saline (saline v. FLX: 49.1±13.6 v. 150.3±29.0, t(10)=2.47, adj. p=0.033), while 
not significantly affecting the dmPFC (saline v. FLX: 3.2±1.8 v. 16.3±6.1, t(10)=1.75, adj. 
p>0.05; Fig. 2-6A). However, KET increased cfos expression both the dmPFC and vmPFC 
(dmPFC: saline v. KET: 3.2±1.8 v. 23.7±5.4, t(8)=3.26, adj. p=0.0098; vmPFC: saline v. KET: 
49.1±13.6 v. 136.8±24.9, t(8)=2.75, adj. p=0.023). Furthermore, the increased vmPFC 
expression in both drug groups was exclusive to the deep cortical layers (layers V-VI: saline v. 
FLX: 31.0±9.8 v. 104.8±19.8, t(10)=2.68, adj. p=0.023; saline v. KET: 31.0±9.8 v. 96.0±14.9, 
t(8)=3.33, adj. p=0.0088; layers I-III: saline v. FLX: 18.1±5.3 v. 45.5±9.8, t(10)=1.79, adj. 
p>0.05; saline v. KET: 18.1±5.3 v. 40.8±10.5, t(8)=1.43, adj. p>0.05; Fig. 2-6B). As above, 
animals that received both FLX and KET showed sleeping postures and similar cfos expression  
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Figure 2-5. Animals were injected i.p. with saline, FLX (20 mg/kg), or KET (10 mg/kg) at 
10:00am and sacrificed two hours later. The prelimbic cortex (D and F) demonstrated increased 
cfos expression following administration of both drugs compared to saline (B), whereas the 
anterior cingulate cortex did not (A, C and E). Scale bar in panel E indicates 0.25mm. 
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Figure 2-6. Animals were administered saline (n=6), FLX (20 mg/kg, n=5) or KET (10 mg/kg, 
n=5) at 10:00am and sacrificed two hours later. FLX and KET selectively activate the vmPFC 
(A), and the deep layers of this region (B), similar to DMI. ‘*’, adj. p<0.05; ‘**’, adj. p<0.01. 
 
  
	   64 
in the regions involved in sleep and arousal compared to control animals, indicating that these 
doses of antidepressant drugs do not significantly influence sleep-wake behavior. 
 
Desipramine activates the nucleus accumbens via the vmPFC 
We next asked whether the limbic structures that receive projections from the vmPFC are also 
activated by DMI (30; 34). We found that drug administration did not significantly activate the 
lateral septum (saline v. DMI: 15.2±2.3 v. 25.3±8.5, t(8)=1.12, p>0.05), insular cortex (saline v. 
DMI: 4.6±2.0 v. 2.3±0.7, t(8)=1.08, p>0.05), nor basolateral amygdala (saline v. DMI: 6.7±1.7 v. 
8.7±3.3, t(8)=0.5, p>0.05) compared to saline injections (Fig. 2-7). On the other hand, the NAc 
exhibited significantly increased cfos expression (saline v. DMI: 10.6±3.2 v. 36.8±9.1, t(8)=2.72, 
p=0.026; Fig. 2-8). As the NAc consists of the core and shell subregions, which are believed to 
subserve separate behavioral functions (36), we analyzed the anatomic specificity of the vmPFC-
dependent activation of the NAc by DMI (Fig. 2-9). We found that DMI significantly increased 
the number of cfos-stained neurons in the NAc core compared to that of controls (saline v. DMI: 
3.9±0.6 v. 16.8±4.7, t(8)=2.73, p=0.026). The NAc shell had about 190% more cfos positive 
neurons after DMI, but this did not reach statistical significance, likely due to the size of the 
standard error (saline v. DMI: 6.7±2.7 v. 20.0±5.2, t(8)=2.27, p=0.053). However, lesions in the 
vmPFC led to decreases in cfos-stained neurons in both structures (DMI, intact v. lesion, NAc 
core: 16.8±4.7 v. 7.7±2.7; NAc shell: 20.0±5.2 v. 9.1±2.4), whereas vmPFC lesions did not 
affect NAc expression when saline was administered (intact v. lesion: NAc core: 3.9±0.6 v. 
9.1±1.1; NAc shell: 6.7±2.7 v. 11.2±4.0). A 2x2 ANOVA confirmed that drug injection alone or 
lesion alone did not cause a significant difference in the group means. Note that although some 
lesions included dorsal peduncular cortex (DPC, as in Fig. 2-8), a tracing study (37), which I 
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Figure 2-7. cfos-labeled cells were counted in the insular cortex (IC), nucleus accumbens (NAc), 
lateral septum (LS), and basolateral amygdala (BLA) in animals given i.p. saline (n=5) or DMI 
(10 mg/kg, n=5). Among these structures, only the nucleus accumbens was selectively activated 
by the drug. ‘*’, p<0.05. 
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Figure 2-8. Cells in the nucleus accumbens are also activated by DMI (10 mg/kg) (C) compared 
to animals that received saline (B). However, cfos staining was reduced when DMI was injected 
into animals with neuronal lesions in the vmPFC (A, E). mPFC: Bregma +3.5mm; NAc: Bregma 
+2.0mm. Scale bars in A and E are 0.5mm. 
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Figure 2-9. Sham- and vmPFC-lesioned animals were administered saline or DMI (10 mg/kg) 
i.p. (10:00am) and sacrificed two hours later. In intact animals, the number of cells that were 
stained by cfos in the NAc was significantly greater in animals that received DMI (n=5) 
compared to those that received saline (n=5). However, the levels of cfos expression in the core 
and shell were reduced by vmPFC lesions (n=6). n=6 for lesion group that received saline 
injection. ‘*’, p<0.05.  
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confirmed, showed that only a few cells in this structure project to the NAc ipsilaterally, whereas 
the vmPFC heavily projects to NAc from both sides. Therefore inclusion of the DPC in lesions is 
unlikely to play a role in cfos counts in the NAc. 
 To examine whether the activation of the NAc by DMI via the vmPFC could be mediated 
by direct projections from the vmPFC to the NAc, we injected the retrograde tracer cholera toxin 
subunit B (CTB) unilaterally into the NAc of the animals (n=4; Fig. 2-10). After surgical 
recovery, we administered DMI as before and stained brain tissue for both CTB and cfos. We 
specifically looked for cells in the vmPFC that had cytoplasmic staining for CTB (brown, DAB) 
and nuclear cfos stain (black, DAB with Ni and Co), which would indicate cells in the vmPFC 
that were activated by DMI and project to the NAc. As before, DMI injection resulted in 
increased cfos staining in the NAc (Fig. 2-11A) and vmPFC (Fig. 2-11C). Of the cell bodies in 
the vmPFC stained with CTB, 12.6±2.1% had cfos-labeled nuclei on the ipsilateral side (Fig. 2-
11D). These results suggest that these neurons are both activated by DMI and project to the NAc.  
 
vmPFC lesions partially block the DMI effect on forced swim test immobility 
Given that the vmPFC appears to be an important structure activated by DMI, I asked whether 
this region was the main avenue by which DMI induces its antidepressant effects. I therefore 
asked whether vmPFC lesions would block the antidepressant effects of DMI in the forced swim 
test (FST). In this procedure, an animal is placed in an escapable container of water for 15 
minutes on day 1. On the second day, the animal is returned to the cylinder for 5 minutes and the 
total time of time spent immobile is measured, for increased immobility is considered to be 
associated with depression. We induced lesions in the vmPFC with ibotenic acid, and 
administered the FST to animals while administering desipramine or saline.  
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Figure 2-10. Retrograde tracer (CTB) injections into the nucleus accumbens of four animals. 
Labels indicate distance from Bregma. 
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Figure 2-11. B Retrograde tracer CTB was unilaterally injected into the NAc (Bregma + 
2.0mm), and upon postsurgical recovery the animal was injected with DMI (10:00am, 10 mg/kg) 
and sacrificed (12:00pm). A indicates opposite side that did not receive injection. C Many cell 
bodies were stained brown in the ventromedial prefrontal cortex, particularly layer V (Bregma 
+3.2mm). The black arrows in D point to cell bodies stained brown for CTB that had cfos 
staining in the nuclei, indicating possible activation by DMI. Scale bars in A, C and D indicate 
0.5mm, 0.5mm and 0.25mm. 
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In intact animals, in comparison to saline-injections (n=5), DMI injections (n=4) reduced 
FST immobility time (saline v. DMI: 53.9±10.7s v. 13.9±2.4s, t(7)=3.25, p=0.014; Fig. 2-12). 
DMI injections into vmPFC-lesioned animals (n=6) also decreased FST immobility time, 
although not to the same levels as in intact animals (n=6; DMI in lesion v. intact: 36.07±7.57s v. 
13.9±2.37s, t(10)=4.28, p=0.0016).  The immobility time of the DMI-treated lesioned animals 
was greater than that in the intact animals DMI-injected animals, but this did not quite reach 
statistical significance (t(8)=2.30, p=0.0507). Furthermore, DMI reduced immobility in the 
lesioned animals, albeit not to the level of intact animals. These results suggest that vmPFC 
lesions may partially block the immobility-reducing effects of DMI in the FST. 
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Figure 2-12. The forced swim test was performed on animals with vmPFC or sham lesions, that 
were administered saline (n=6 for each) or DMI (sham: n=4, lesion: n=5). Lesions increased 
immobility time in saline- and particularly DMI-treated animals, but did not reach statistical 
significance (saline: 0.0836, DMI: p=0.0507).  
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Discussion 
Although antidepressant medications have been used for decades, how and where they work in 
the brain is unclear. In this study, we found that acute administration of the tricyclic 
antidepressant desipramine, selective serotonin reuptake inhibitor fluoxetine, and NMDA-
antagonist ketamine selectively activate a common set of structures in the rat brain, including the 
ventromedial prefrontal cortex. All three drugs also selectively target the deep layers of the 
vmPFC, which contain neurons that project to the striatum, hypothalamus, and brainstem, 
suggesting that specific neurons within the vmPFC may be important in mediating the drug 
effect.  In addition, we found that the nucleus accumbens (NAc), a structure implicated in MDD, 
was also activated by DMI, and that this activation was dependent on the vmPFC. Finally, 
vmPFC lesions increased immobility in the FST, a behavior that has been associated with 
depression.  DMI was still partially effective in reducing the immobility time even in the vmPFC 
lesioned rats, but although the immmobility time was still three times that of intact, DMI-treated 
rats, this difference did not quite reach statistical significance.   It should be noted that in the 
subsequent chapter, I found a significant increase in FST immobility in vmPFC-lesioned animals 
compared to sham-lesioned animals, whereas here statistical comparison of saline-injected sham-
lesioned animals and vmPFC-lesioned animals did not quite reach significance (p=0.08). This 
may be because the three i.p. injections, despite being of saline, differentially affects sham-
lesioned and vmPFC-lesioned animals, particularly stressing the sham-lesioned animals and thus 
making the difference between the groups less pronounced. This possibility is supported by the 
finding that immobility times in the vmPFC-lesioned groups with and without i.p. saline were 
similar (76.0±5.5s v. 66.0±6.8s, t(26)=0.74, p=0.46), whereas for the sham-lesioned groups with 
and without i.p. saline were dissimilar (53.9±10.7s v. 24.9±4.0s, t(9)=2.92, p=0.017). In addition, 
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i.p. injections introduced greater variability in the control group which likely contributed to the 
lack of statistical significance. 
 
Technical considerations 
One caveat to our findings is that we used healthy animals in our experiments, and it is 
conceivable that depression in humans may depend upon different circuitry.  However, because 
we started with circuitry that is activated by antidepressants, our results are likely to apply to the 
antidepressant effects of DMI and other antidepressant drugs in humans.  Another technical issue 
is that the dosages of antidepressant drugs that we used were derived from earlier literature about 
drug effects on tests in rats that have been thought to improve depression-like behaviors.  
However, the dosage at which the drugs may work in actual depression in humans may be 
different.  Nevertheless, the results from functional imaging studies support that the vmFPC is 
likely to play a role in human depression, and that antidepressant drugs alter that activity. 
 
 
Why do antidepressants selectively activate the deep layers of the vmPFC? 
The vmPFC, as opposed to the dmPFC, has many connections to limbic areas of the brain that 
are involved in the control of emotion and mood (38). DMI is a reuptake inhibitor of 
norepinephrine and serotonin, and FLX is a serotonin reuptake inhibitor, so the increased 
extracellular concentration of these neurotransmitters may result in the activation of cells in the 
deep layers. For instance, there is evidence that alpha-2 receptors (alpha-2R) mediate NE action 
in depression, as alpha-2R antagonists blocked the effect of DMI in reducing immobility in the 
FST (39). However, the cellular elements where the alpha-2Rs are located are not fully 
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understod. There is evidence that presynaptic alpha-2R’s moderate norepinephrine release (40), 
but that they also are on that they are on cortical GABAergic interneurons (41). The latter report 
provides evidence that alpha-2Rs cause cellular hyperpolarization, so they propose that 
norepinephrine reuptake inhibitors may be causing excitation in the vmPFC by disinhibiting 
pyramidal cells via inhibitory interneurons. 
As for serotonin, it is estimated that 80% of PFC pyramidal cells contain both 5-HT1A 
and 5-HT2C receptors (42). However, the inhibitory effect of 5-HT1A receptors is believed to 
dominate the excitatory 5-HT2C receptors due to their localization around the soma and axon 
initial segment. In addition, a recent study showed that most of the fast-spiking interneurons in 
the rat mPFC are inhibited via the 5-HT1A receptors (43). Therefore, the net excitaory effect on 
the pyramidal cells in the vmPFC may also result from inhibition of the interneurons.  
Pyramidal cell activation in the vmPFC by ketamine is also likely through interneurons, 
as KET blocks excitation by glutamate receptors. Low doses of KET in the mPFC may reveal its 
affinity for interneurons, and result in blockage of the inhibitory effects on pyramidal neurons 
(44). We therefore hypothesize that the vmPFC interneurons that inhibit deep-layer pyramidal 
cells are more sensitive to glutamate and the monoamines than the pyramidal neurons. 
However, it is unclear why layers V-VI pyramidal neurons in this region are selectively 
activated following administration of the drugs, while the pyramidal cells in layers II-III are not. 
The localization of receptor subtypes may provide a clue; for instance, 5-HT2C receptor mRNA 
expression is light in the superficial layers of the mPFC (45), and there appears to be increased 
expression of 5-HT1A receptor mRNA in the vmPFC layer VI (46). However, in the mPFC 
receptors are not necessarily localized to the cell layer that they influence, and thus an 
explanation for the cfos expression pattern in the mPFC remains to be elucidated.  
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Is neuronal plasticity a common endpoint of all three drugs?  
One of the key questions in comparing various classes of antidepressant drugs is whether their 
effects ultimately converge on the same molecular and physiological endpoints to produce their 
mood-elevating effects. The deep layers of the mPFC project to subcortical regions (47), so 
specific activation of the deep-layer cells may increase activation of the downstream limbic 
structures (see below). On a cellular level, the prevailing hypothesis is that enhancing 
neuroplasticity is key to combating depression, given that stress leads to dendritic atrophy (48) 
and depressed patients have decreased gray matter volumes (8). There is mounting evidence that 
ketamine in particular encourages synaptic growth, including increased spine density and new 
spine formation (22). Furthermore, as mentioned above, blocking a pathway important for cell 
growth and survival prevents synaptogenesis and blocks the behavioral antidepressant response 
(22), pointing to a potential link between neuroplasticity and the antidepressant effect. 
 
Evidence that the rodent vmPFC plays a role in depression 
The rodent vmPFC is a growing focus of depression research because some believe it – 
particularly the infralimbic region – is most homologous to the human subgenual prefrontal 
cortex (BA25; 30; 31), which has been reported to show changes in activity in depressed patients 
(see above). The projection patterns of the rat vmPFC and non-human primate BA25 are very 
similar (24; 30). There is preclinical evidence that the rodent vmPFC may be linked to 
depression-like outcomes. For instance, chronic social defeat stress resulted in decreased levels 
of transcripts for Zif268, an immediate early gene, in the rat infralimbic cortex (51), suggesting 
that the vmPFC in stressed animals may have impaired function. More recently, deep brain 
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stimulation (DBS) was performed in rats (49) and optogenetic stimulation in mice (52) targeting 
the vmPFC. DBS decreased immobility in the FST, appeared to decrease anxiety and reduce the 
effects of footshock stress. Optogenetic stimulation increased cfos and Zif268 mRNA expression 
(where?) that was normally reduced following chronic social defeat stress, and reversed 
depression- and anxiety-like behaviors in a battery of tests. Furthermore, our work in the current 
study and that in Chapter 3 of this dissertation has shown that vmPFC lesioned animals 
demonstrate depression-like behaviors: increased rapid eye movement (REM) sleep, shortened 
REM latency, and increased immobility in the forced swim test. In contrast, dmPFC-lesioned 
animals only showed increased REM sleep. Altogether, these findings suggest that the vmPFC 
may be important in both the expression of depression-like behaviors and mechanism of 
antidepressant therapies. 
 
NAc activation by DMI 
Along with the vmPFC, the NAc was the only limbic region I found that showed significant 
activation with DMI compared to saline-injected control animals. The NAc normally plays a role 
in reward and motivated behavior to both conditioned and unconditioned stimuli; thus it is 
widely believed that NAc dysfunction leads to anhedonia (53). Our finding that DMI activates 
the NAc via the vmPFC indicates that this circuit may be particularly important in antidepressant 
action. However, the NAc cells that are activated by the drug remain to be characterized.  In 
contrast to our results following acute administration, chronic administration of clomimpramine 
(a tricyclic antidepressant) and fluoxetine were found to reduce neuronal firing rates in the NAc 
(54).  As chronic administration is required to achieve improvement in human depression, 
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together these findings suggest that the transition from activation to reduced firing in the NAc 
may be important for the benefits of antidepressant treatment.  
We did not detect drug-induced changes in cfos expression in the insular cortex, lateral 
septum or basolateral amygdala that receive projections from the vmPFC. It is possible that 
limitations in our methods and limited sample size did not allow the detection of cellular 
activation in these regions. For instance, there may be a neuronal subpopulation within a 
structure that is activated by the antidepressant drugs, but due to the size of the subpopulation an 
increase in cfos expression could not be detected compared to control animals. Another potential 
explanation is that a population of cells that is activated by the drugs does not express cfos, as 
expression of the protein has been associated with specific neuronal firing patterns in some cell 
groups (55). 
 
Comparison to published literature 
Two similar cfos-induction studies using antidepressant drugs have been completed in the past. 
In the first, Beck reported that neither desipramine (10 mg/kg) nor fluoxetine (15 mg/kg) 
increased cfos expression in the infralimbic cortex (the prelimbic cortex was not observed), and 
DMI did not increase cfos in the nucleus accumbens core (56). In addition, DMI did induce cfos 
expression in the anterior cingulate cortex compared to that of saline-injected animals. These 
discrepancies can be explained by a few factors: in the previous study, no apparent effort was 
made to control for circadian influences on cfos expression; and the same (0.5mm) counting box 
was used to count cells for every structure. The latter may contribute to the discrepancy because, 
as we have shown, some structures do not display uniform cfos expression following drug 
treatment and thus counting boxes that do not include the deep layers of the vmPFC are likely to 
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miss the changes in cfos expression.  In addition, we only included animals that displayed cfos 
expression patterns characteristic of sleep, because awakened animals tend to have much greater 
cfos expression in the cortex and elsewhere. Therefore, we believe that by using sleeping animals 
we reduced variability. 
In another recent paper by Miyata and colleagues, cfos expression was observed 
following fluoxetine administration (5 mg/kg and 10 mg/kg; 54). They reported that fluoxetine 
increased cfos expression in the NAc shell but not core, which is the opposite of our findings. In 
addition, they reported that cfos was not induced in the prelimbic cortex (which they call 
‘cingulate cortex area 3’). These discrepancies are most likely due to their counting method, as 
they used a small counting box (380um x 380um) that were apparently centered on each 
structure, thus making it very likely that cells in the deep layers of the prelimbic cortex were not 
counted. In addition, they also did not appear to control for circadian timing or the influence of 
wakefulness on cfos expression. 
 
Conclusion 
Although traditional antidepressant drugs such as tricyclic antidepressants and selective 
serotonin reuptake inhibitors require up to a few weeks to take effect, investigating their acute 
neural targets may allow us to understand the important circuitry involved in their mechanism of 
action. Our findings that three different classes of drugs with demonstrated antidepressant 
properties selectively target the vmPFC strengthen the notion that this region is important in 
antidepressant action and mood regulation. In the future, it will be imperative to investigate how 
the acute response develops into the mood-elevating chronic response in TCAs, SSRIs and other 
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drug classes, and whether their antidepressant effect is dependent on neuroplasticity, such as 
synaptic growth and changes in cell morphology. 
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Chapter 3 
 
Medial prefrontal cortex regulates depressive 
behavior and REM sleep 
 
 
ABSTRACT 
 
Major depressive disorder (MDD) is a debilitating disease that is diagnosed by its symptoms, 
such as persistent depressed mood and disturbances in sleep. The prefrontal cortex (PFC) has 
been implicated as an important structure in the neural circuitry of MDD, for there are 
pronounced abnormalities in blood flow and metabolic activity in PFC subregions, including the 
subgenual cingulate cortex (SGC, or Brodmann area 25). In addition, deep brain stimulation in 
the SGC has recently been shown to alleviate treatment-resistant depression. Depressed patients 
also show characteristic changes in sleep: insomnia, increased rapid-eye-movement (REM) sleep 
and shortened REM sleep latency. We hypothesized that sleep changes may be a consequence of 
the abnormal PFC activity in depressed patients. The rat ventromedial PFC (vmPFC) has been 
likened to the human subgenual cingulate cortex, so I made excitotic lesions in the vmPFC and 
the adjacent dorsal region (dmPFC). I found that both dmPFC and vmPFC lesions led to 
increased REM sleep, however only the vmPFC-lesioned animals displayed shortened REM 
latency and increased immobility in the forced swim test. These results support my hypothesis 
that the human homolog of the rat vmPFC, the SGC, may be a critical area for modulating both 
mood and REM sleep. 
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Introduction 
Depression is the leading cause of disability worldwide, and continues to increase in prevalence 
(1). Known clinically as Major Depressive Disorder (MDD) in the U.S., it is diagnosed by the 
presence of at least five symptoms, which must include depressed mood or anhedonia (2). 
Examples of the other criteria are changes in appetite, loss of energy, and sleep disturbances. 
Despite the prevalence of MDD (and other mood disorders), its etiology remains unclear. It is 
generally believed that MDD is caused by dysfunction in a network of structures in the brain, 
rather than a single structure. This network is believed to include the prefrontal cortex, 
hippocampus, nucleus accumbens, and amygdala, based on their function and human imaging 
studies (3). 
The prefrontal cortex (PFC) has particularly been of interest because of the marked 
changes in activity in depressed patients compared to healthy controls. For instance, the ventral 
regions demonstrate an increase in cerebral blood flow (4) and metabolic activity (5), whereas 
the dorsolateral PFC displays reduced activity (6–8). The subgenual cingulate cortex (SGC or 
Brodamann area 25), which is included in the PFC by many clinical researchers (9–12), shows 
increased glucose metabolism (13). Furthermore, responders to antidepressant treatment have 
significantly reduced activity in the SGC compared to their pre-treatment baseline levels (14). 
Preclinical studies also provide supporting evidence for the importance of the medial 
prefrontal cortex (mPFC) in depression-associated behaviors. Human postmortem studies have 
shown reduced glial cell counts in MDD patients (15), and glial cell ablations in the rat mPFC 
resulted in behaviors that have been associated with depression, including decreased sucrose 
consumption in the sucrose preference test and increased immobility in the forced swim test (16). 
Excitotoxic neuronal lesions in the rat mPFC also led to ‘learned helplessness’ upon exposure to 
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inescapable footshocks (17). In addition, chronic stress protocols, which are believed to induce 
behaviors that are depression-like, led to decreased glial cell count (16) and dendritic atrophy 
(18). Interestingly, deep brain stimulation in the mPFC induced an antidepressant-like response 
in the forced swim test (19), and optogenetic stimulation in the mPFC of mice susceptible to 
social defeat stress reversed their avoidance of social interaction and increased their preference 
for sucrose (20). Altogether, these results suggest that inactivation of the rodent mPFC region is 
associated with depression-like outcome measures, whereas stimulating this region may produce 
antidepressant-like effects. 
The role of insomnia with daytime fatigue as a diagnostic criterion for MDD is intriguing 
because it suggests a biological relationship between sleep and affect. Depressed patients 
complain of insomnia and demonstrate increases in REM sleep, along with decreased REM 
latency (the interval of time between sleep onset and REM sleep onset) (21–23). However, it is 
uncertain whether these sleep changes are related to the cause of MDD or are a consequence of 
it. Animals that undergo a chronic mild stress protocol demonstrate changes in sleep similar to 
those observed in depressed humans, suggesting these sleep changes may be secondary (24). 
However, most classes of antidepressant drugs suppress REM sleep, suggesting that treatment 
may be related to reversing the REM sleep changes (25). Even more perplexing, acute sleep 
deprivation has been found to effectively (albeit very temporarily) elevate mood, despite that 
most depressed patients suffer from insomnia (26). I was interested in exploring the depression-
sleep relationship by investigating the neural circuitry of both depression and sleep, using the rat 
as a model of study. 
I hypothesized that prefrontal cortex dysfunction may be key in producing depression-
associated behaviors, including sleep disturbances. I made neuronal lesions in the ventral and 
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dorsal subdivisions of the rat medial prefrontal cortex and tested the animals for depressive-like 
behavior in an established rodent model of depression and sleep-wake behavior. I subsequently 
propose a model of sleep modulation via the prefrontal cortex.  
 The forced swim test (FST) was used to test depression-like behaviors (27; 28). The test 
was originally established to predict antidepressant efficacy, but it has been demonstrated that rat 
models of depression lead to increased immobility in the FST, such as the Flinders Sensitive 
Line (a genetic model of depression cite), and following chronic stress (29; 30) and social defeat 
protocols (31; 32). The FST is therefore generally believed to have validity, albeit limited, as an 
animal model of depression-associated behaviors (35). 
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Methods 
Animal Surgery and EEG/EMG Implantation 
Prior to surgery, animals were anesthetized with ketamine-xylazine (i.p., 800 mg/kg ketamine, 
80 mg/kg xylazine, Med-Vet, Mettawa, IL) and then placed on a stereotaxic frame so that their 
head was fixed. Injections of ibotenic acid (IBO, Tocris, Ellisville, MO), 0.9% saline (Med-Vet, 
Mettawa, IL) or neural tracer (BD, Molecular Probes, Grand Island, NY or CTB, List Biological, 
Campbell, CA) were administered directly into the brain using a fine glass pipette (1 mm glass 
stock, tapering slowly to a 10-20um tip) connected to an air compression system. A series of 20-
40psi puffs of air were used to deliver the compounds into and with the following coordinates 
(Paxinos and Watson, 2005) and volumes: ACC (dmPFC): AP+3.0 mm to 3.5 mm  DV-1.4 mm 
RL+/-0.6 mm, 66nL 1% - 5% IBO; vmPFC: AP+3.0 mm to 3.5  mm, DV-3.4 RL+/-0.6 mm, 66-
99nL 5% IBO, 16.5nL 1% CTB; vlPAG: AP-7.2 mm,  DV-5.6 mm,  RL-1.2 mm, 33nL 1% CTB; 
SLD: AP-9.4 mm, DV-6.3 mm,  RL-1.2 mm, 16.5nL 1% CTB. 
On the same day some of the animals received four 3.2mm EEG screw electrodes 
(Plastics One, Roanoke, VA) that were screwed into skull, one on each side of the frontal and 
parietal bones. Two flexible EMG wire electrodes (Plastics One, Roanoke, VA) were also placed 
on the left and right nuchal muscles. The free ends of the leads were placed in a plastic electrode 
pedestal (Plastics One, Roanoke, VA) that was cemented onto the skull using Jet Denture Repair 
Powder and Jet Liquid (Henry Schein, Melville, NY). Any animals that did not receive 
electrodes had their incision closed with wound clips. Upon completion of the procedure, the 
animal was given a subcutaneous injection of analgesic meloxicam (1.0 mg/kg, Med-Vet, 
Mettawa, IL) and allowed to recover on a warm plate until awakened from anesthesia.  
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Sleep Recordings and Analysis 
After at least a week of post-surgical recovery, animals undergoing sleep recordings were placed 
in isolated recording chambers. Flexible cables (Plastics One, Roanoke, VA) that were mounted 
to fixed commutators were attached to the electrode pedestals, and the cages were placed such 
that the animals could move freely. As before, food and water were available ad libitum, ambient 
temperature was controlled, and the light:dark cycle was 12:12 with lights on at 8:00 am. Video 
cameras were placed to capture movement in the entire cage, and the animals were habituated 
without disturbance for at least two days and then recorded for 48h using VitalRecorder (Kissei 
Comtec Co., Nagano, Japan). Upon completion of the recordings, animals were detached from 
the cables and returned to the holding room. 
The EEG/EMG recordings were analyzed using SleepSign (Kissei Comtec Co., Nagano, 
Japan). The recordings were divided into 12s epochs and each epoch scored manually as wake, 
REM, or NREM sleep. Wake was identified by high-frequency, desynchronized EEG 
accompanied by frequent EMG activity and observed behaviors on the video playback. NREM 
sleep was identified by the dominant presence of high-amplitude, low-frequency (<4 Hz) EEG 
activity and little muscle tone on the EMG recording. REM sleep was identified by theta waves 
(4-7 Hz) of consistent low amplitude on the EEG recording accompanied by very low EMG 
activity. 
Sleep-wake percentages, bout numbers and bout durations were analyzed using unpaired 
t-test and adjusted using Bonferoni’s correction, using a significance threshold p<0.05.  
 
Spectral analysis 
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NREM and REM spectral analyses for control (n=5), dmPFCx (n=7), and vmPFCx (n=20) were 
conducted by re-scoring sleep 2-4p with 4s epochs, while wake was analyzed during 8-10p. 
Transitions and movement artifacts were removed from the analyses, and cases with high 
amounts of artifact were omitted. Waveforms in each vigilance state were grouped into 
frequency bands and analyzed using one-way ANOVA with the post-hoc Scheffe test for 
multiple comparisons, using a significance threshold p<0.05. 
 
Statistical Analysis of Forced Swim Test 
FST immobility between groups were analyzed using unpaired t-test and adjusted using 
Bonferoni’s correction, using a significance threshold p<0.05. Both dmPFCx and vmPFCx lesion 
groups were included in the correlation analysis comparing FST and REM sleep latency. 
 
Histology and Immunohistochemistry 
Brains were sliced into four series of 40um sections using a freezing microtome. The sections 
were stored in PBS-0.02% azide in 20°C.  
Immunohistochemical staining was completed as follows: tissue sections were rinsed in 
PBS three times, 3-5 min each. They were then incubated for 30 min in 0.3% H2O2 (Sigma, St. 
Louis, MO) in PBT (phosphate buffer with Triton X-100; Sigma, St. Louis, MO) to oxidize any 
remaining blood. The sections were again rinsed in PBS and then incubated in primary antibody 
diluted in PBT-Azide for 1-2 nights, depending on the antibody (NeuN, MAB377, mouse 
monoclonal, 1:20,000, Chemicon, Billerica, MA). Tissue were then rinsed in PBS three times, 
and incubated in secondary antibody (1:1000, biotin SP-conjugated against appropriate species 
IgG, Jackson ImmunoResearch Laboratories, West Grove, PA) for 60-90 min. Sections were 
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again rinsed in PBS and placed in ABC solution (1:1000 each Vectastain solutions A and B, 
Vector Laboratories, Burlingame, CA) for 60-90 min. Sections were rinsed in PBS and stained 
for 5 min in a solution consisting of: 1% DAB, 0.3% H2O2 (and 0.01% Ni, 0.005% CoCl2 if 
desired a black stain). Staining procedure for BD started with ABC solution because the tracer is 
biotinylated. Tissue were then rinsed in PBS and mounted on microscope slides in gelatin. 
Slides were counterstained by placing them in ddH2O for 5 min, followed by 10-30 sec in 
0.1% thionin (Sigma, St. Louis, MO). The slides were dehydrated step-wise by incubating in 
50% EtOH, 70% EtOH, 95% EtOH, and 100% EtOH for 2 min each. Slides were then placed in 
xylene for several hours before covering with glass coverslips.  
For CTB and BD double immunofluorescence staining, sections were rinsed and 
incubated in primary antibody as stated previously. Following rinses in PBS, sections were 
incubated in Alexa Fluor 488 (A11055, anti-goat, 1:1000, Molecular Probes, Grand Island, NY) 
and Cy3-conjugated streptavidin (016-160-084, 1:500, Jackson ImmunoResearch Laboratories, 
West Grove, PA). Sections were rinsed and mounted on microscope slides under dim light. The 
fluorescent cells were imaged on a confocal microscope (Zeiss, Thornwood, NY) at 63x 
magnification, at a single optical layer.  
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Results 
Cell body-specific lesions of the rat mPFC increase REM sleep and sleep fragmentation 
Sleep-wake behavior was investigated after placing bilateral ibotenic acid lesions in the dorsal 
(anterior cingulate cortex, dmPFCx, n=9) or ventral mPFC (infralimbic and prelimbic cortex, 
vmPFCx, n=24) of adult male Sprague-Dawley rats. Photomicrographs of the lesions are shown 
in Fig. 3-1 and schematic drawings of lesions in a representative set of brains is shown in Fig. 3-
2. Lesions that significantly extended into the premotor cortex (M2) or orbital frontal cortex 
were excluded from the analyses. Control animals were treated identically except they received 
injections of 0.9% saline (n=10). 
Following placing the lesions, EEG and EMG electrodes were implanted into the skull 
and on the neck muscles, respectively, for recording sleep-wake behavior. After at least1 week 
for recovery, the animals were habituated to an isolated chamber and subsequently recorded for 
48 hours. Neither lesion group exhibited statistically significant changes in total wake or NREM 
sleep over 24 hours, but both groups demonstrated a marked increase in REM sleep compared to 
control animals (dmPFCx: p=0.00035, adj. p=0.001, t(17)=3.95 and vmPFCx: p=0.016, adj. 
p=0.048, t(31)=2.05). Animals with lesions in the dmPFC had a 20.7% increase in REM, while 
vmPFCx animals had a 16% increase (Fig. 3-3B). Both groups also had increased sleep 
fragmentation. In particular, the vmPFCx animals demonstrated increased bout numbers of wake 
(32.1%, p=4.5*10^-5, adj. p=0.00014, t(31)=4.35) and NREM sleep (26.1%, p=8.1*10^-5, adj. 
p=0.00024, t(31)=4.14) during the light period (Fig. 3-3C). The vmPFCx animals also had 
shorter wake (-33.5%, p=0.00036, adj. p=0.0011, t(31)=3.61) and NREM sleep bouts (-26.0%, 
p=0.00018, adj. p=0.00054, t(31)=3.86) during the light period, and shorter NREM sleep bouts  
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Figure 3-1. A mPFC histology of saline-injected control rat brain stained with NeuN. Ibotenic 
acid injections killed neurons in the dmPFC B and vmPFC C. Bregma +3.5mm. 
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over the 24 hours (-18.3%, p=0.00097, adj. p=0.003, t(31)=3.23) (Fig. 3-3D). dmPFCx animals 
had 25.4% greater bout numbers of REM sleep over the 24 hours (p=0.0088, adj. p=0.026, 
t(17)=2.43). The increased sleep fragmentation during the light period can be observed in the 
hypnograms in Fig. 3-4.  
The vmPFCx (-24.7%, p=0.0038, adj. p=0.012, t(31)=2.69), but not the dmPFCx 
(p>0.05, t(17)=1.04) animals, had significantly reduced REM latency (Fig 3-5). Altogether, the 
results from the sleep-wake analysis suggest that the ventral and dorsal mPFC both influence 
REM sleep amounts, but only lesions in the ventral region lead to a pronounced increase in sleep 
fragmentation and shortened REM sleep latency.  
Spectral analysis of wake, REM sleep and NREM sleep demonstrated that the dmPFCx 
group had an increase in delta power during NREM sleep (30.8%, p=0.011, t(17)=2.85), along 
with decreases in alpha (-26.2%, p=0.029, t(17)=2.38) and beta+gamma power (-30.3%, 
p=0.022, t(17)=2.52). The vmPFCx group was not significantly different from controls in any of 
the vigilance states (Fig. 3-6). 
 
Cell body-specific lesions of the rat vmPFC increase immobility in the FST 
To investigate if the dmPFC and/or vmPFC may modulate depression-like behaviors, I tested a 
subset of the lesioned and sham-lesioned animals under the forced swim test (FST) paradigm 
(24). Briefly, an animal is placed in a cylinder of 25°C water for 15 minutes on Day 1, and 5 
minutes on Day 2. An increase in the total length of time an animal spends immobile during the 
Day 2 test session is believed to indicate that an animal is exhibiting depression-like behaviors. 
The results showed that vmPFCx animals had 165.3% increased immobility (p=0.0044, adj. 
p=0.013, t(26)=2.66), while the dmPFCx animals were not statistically different from controls  
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Figure 3-4. Hypnograms of individual cases from each group exemplify increased fragmentation 
(shorter and increased number of bouts) during the rest (lights on) period in the lesion groups 
compared to controls. 
 
 
 
  
 106 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5. The vmPFCx, but not the dmPFCx, animals had shortened REM latency compared 
to controls. This measure was calculated by averaging the interval of time between the onset of 
NREM sleep and REM sleep for each sleep episode over 24h. ‘*’, adj. p <0.05. 
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Figure 3-6. Spectral analysis of wake, REM and NREM sleep. A Frequency spectra of wake, 
REM sleep and NREM sleep of the three experimental groups. B Frequency data were grouped 
according to frequency bands correlating to delta (0.25-4 Hz), theta (4.0-9.0 Hz), alpha (9.0-15.0 
Hz) and beta+gamma waves (15.0-60.0 Hz). Results were compared using one-way ANOVA 
with post-hoc Scheffe test: ‘*’, adj. p<0.05. Sleep states were analyzed from 4s epochs scored 
between 2:00pm and 4:00pm. Wake was analyzed from 4s epochs scored between 8:00pm and 
10:00pm. 
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(p>0.05) (Fig. 3-7). Fig. 3-8 shows immobility bouts during the 5-minute test session from 
representative animals in each group.  
 
Immobility in the Forced Swim Test negatively correlated with REM sleep latency 
Because vmPFCx animals exhibited shortened REM latency and increased immobility in the 
FST, both of which are characteristic of depression-like states, such as seen after chronic stress 
in rodents, I next asked whether these two behaviors were associated among all of the lesioned 
animals. A correlation analysis showed that the measures are significantly negatively correlated 
(R=-0.464, p=0.019; Fig. 3-9), suggesting that the two measures may depend upon the same 
substrate.  
 
Neural circuit of mPFC regulating REM sleep 
To determine what the substrate of the REM suppression may be, I examined the projections 
from the mPFC to the ventrolateral peiaqueductal gray matter (vlPAG).  Lu and colleagues (38) 
had previously shown that the vlPAG and adjacent lateral pontine tegmentum (vlPAG-LPT) 
contains GABAergic neurons that inhibit the sublaterodorsal nucleus (SLD), which promotes 
REM sleep (38), suggesting that the vlPAG-LPT suppresses REM sleep.  Other earlier tracing 
studies had shown that both vmPFC and dmPFC neurons send projections to the vlPAG-LPT 
(39; 40). To investigate whether each mPFC region may be modulating sleep via direct 
projections to this REM control site, I injected the anterograde tracer biotin dextran (BD) into the 
vmPFC or dmPFC and retrograde tracer cholera toxin B (CTB) into the SLD in the same animals 
(Figs. 3-10 and 3-12). I then examined the results of immunohistochemical staining for BD and 
CTB in the vlPAG-LPT. 
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Figure 3-7. Average time animals in each experimental group were immobile during the 5min 
forced swim test. The vmPFCx, but not the dmPFCx animals had increased immobility 
compared to control animals. ‘*’, adj. p <0.05. 
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Figure 3-8. Example schematic of immobility bouts during the forced swim test as scored by 
Ethovision. The software compares dynamic pixel changes frame-to-frame, and if less than the 
threshold percentage of pixels differs between frames the animal is considered immobile. 
Parameters were validated by manual scorers (1). 
  
 111 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-9. The time an animal was immobile during the FST was plotted v. their REM latency 
measure during sleep. A significant correlation between these measures was found (R=-0.464, 
p=0.019), suggesting a possible biological relationship between these two measures.  
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Of the retrogradely labeled cell bodies in the vlPAG-LPT, 24.2% had appositions from 
the dmPFC and 16.0% had appositions from the vmPFC. A series from each case was labeled 
with fluorescent antibodies and viewed under a confocal microscope to confirm the appositions 
(Figs. 2-11 and 2-13). The injection in Fig. 3-12B includes part of the parabrachial nucleus (PB). 
A retrograde tracing study where CTB was injected only into the PB demonstrated that some 
cells in the vlPAG do project to the PB, but there are none in the LPT (Fuller and Lu, 
unpublished observations). Therefore, some of the cells counted in the analysis may also include 
vlPAG->PB cells.  
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Figure 3-10. To investigate a possible pathway by which the dmPFC may be modulating REM 
sleep, two tracers were injected (both unilaterally) into an individual animal: A BD, an 
anterograde tracer, into the dmPFC (Bregma 3.5mm); B CTB, a retrograde tracer, into the REM-
on SLD (Bregma -9.4mm). C Cells in the vlPAG-LPT (Bregma -7.2mm) were then sought that 
were stained for CTB (brown) and also had BD boutons (black) (D). 
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Figure 3-11. A series from the same case as in Fig. 3-10 was stained with AlexaFluor488 (green, 
CTB) and Cy3 (red, BD) and viewed under a confocal microscope (63x). A cell in the vlPAG is 
stained green, indicating it projects to the SLD area, and has a red bouton from the vmPFC 
(arrow). This image was taken in a single optical plane.  
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Figure 3-12. As in Fig. 3-10, two tracers were injected into an individual animal: A BD, an 
anterograde tracer, into the vmPFC (Bregma 3.5mm); B CTB, a retrograde tracer, into the REM-
on SLD (Bregma -9.4mm). C Cell bodies in the vlPAG-LPT (Bregma -7.2mm) were then sought 
that were stained for CTB (brown) and also had BD boutons (black) (D). 
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Figure 3-13. A series from the same case as in Fig. 3-12 was stained with AlexaFluor488 (green, 
CTB) and Cy3 (red, BD) and viewed under a confocal microscope (63x). A cell in the vlPAG is 
stained green, indicating it projects to the SLD area, and has a red bouton from the vmPFC 
(arrow). This image was taken in a single optical plane. 
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Discussion 
While previous studies have identified the mPFC as an important region underlying MDD, how 
this region affected depression-associated behavior was unknown. In the present study, I 
investigated the roles of the dorsal and ventral subregions in the rat mPFC on sleep and 
depression-like behavior in the forced swim test. I found that ventral and dorsal mPFC lesions 
led to increased REM sleep, but only ventral mPFC lesions led to decreased REM latency, 
pronounced fragmentation, and increased immobility in the forced swim test. Although sleep in 
rodents is generally not as consolidated as in humans, nevertheless, increased fragmentation in 
rodent sleep may be analogous to a greater sleep-wake transitions seen in humans. Interestingly, 
the REM latency and FST measures were significantly correlated. Furthermore, neurons in the 
mPFC terminate on cells in the brainstem that are implicated in suppressing REM sleep, 
suggesting a possible mechanism of cortical REM modulation. Collectively, our results suggest 
that reduced activity in the vmPFC, distinct from the dmPFC, is important in causing the 
depression-associated behaviors of increased REM sleep, decreased REM latency, increased 
sleep fragmentation and increased immobility in the FST. 
 Our experimental methods had a few limitations. First, I only used one traditional rodent 
behavioral test for depression, the forced swim test (FST). This test may only be examining one 
aspect of a multifaceted disorder. However, as depressed patients and chronically stressed 
rodents have characteristic changes in sleep (24), sleep measures may be a useful addition to the 
standard battery of tests used. Second, in my spectral analysis I am unable to determine whether 
the significant changes in NREM power frequency bands were primarily due to an increase in 
slow-frequency bands or a decrease in high-frequency bands. Our method requires normalizing 
every epoch of each case (because of high EEG variability between animals), but as a 
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consequence the underlying reason for a shift in power distribution cannot be distinguished. 
Lastly, I used cholera toxin B (CTB) as a retrograde tracer, which strongly labels cell bodies but 
not dendrites. Descending projections from the cortex are likely excitatory and therefore 
dendritic, but I was unable to observe these contacts. Therefore I likely am underreporting the 
number of appositions.  Nevertheless, the substantial numbers of appositions observed support 
our hypothesis that the mPFC excites neurons in the vlPAG-LPT. 
Two papers published in the past several years have also examined the FST in mPFC-
lesioned animals. Bissiere et al. (41) found that dmPFC-lesioned animals do exhibit a 
depression-like phenotype, contrary to our results. Given that their lesions were incomplete, 
particularly in the rostral dmPFC, it is surprising to find that they show an affect in the FST. One 
possibility is that their rats were tested over a 6-hour clocktime range, so the results may have 
reflected measurements at different circadian phases (42). I attempted to avoid any such effects 
by testing all our animals within the same 90-minute window of each day. Hamani et al. (19) 
lesioned the vmPFC and found that their animals did not show increased immobility in the FST. 
They primarily targeted the infralimbic cortex, as evidenced by their text as well as their 
coordinates. In addition, the single lesion histology section provided was located more caudally 
than our target. As I aimed to lesion both the prelimbic and infralimbic cortices, our larger 
dorsal-ventral range or more rostral location may account for a different result.  
 
The rat mPFC and sleep circuitry 
The dmPFC (anterior cingulate cortex) primarily projects to other neocortical regions, 
particularly premotor regions and the vmPFC, and parts of the medial and mediodorsal thalamus 
(43). The vmPFC (prelimbic and infralimbic cortices) primarily projects to limbic, hypothalamic, 
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and brainstem areas (44). The only region that both dorsal and ventral mPFC areas project to that 
has been shown to specifically modulate REM sleep is the vlPAG-LPT. Therefore, we 
hypothesized that REM sleep changes following dmPFC and vmPFC lesions were caused by loss 
of direct projections to the area. Descending cortical neurons are predominantly excitatory, so 
loss of excitatory projections to the REM-off vlPAG-LPT could have led to an increase in REM 
sleep. However, the finding that shortened REM sleep latency is unique to vmPFCx animals 
suggests that entry into REM sleep may be modulated by neural circuitry that is specific to this 
region. As REM sleep latency has been associated with affect disorders, it may be related to the 
finding that lesions here also lead to increased immobility in the FST. 
I found a unique change in NREM sleep power distribution in the dmPFCx animal group. 
The delta frequency band was significantly increased, whereas the higher frequency bands were 
significantly decreased compared to control animals. These changes reflect a shift in distribution 
of power during NREM sleep. However, a potential source for this shift is unknown. The dmPFC 
has few projections to the basal forebrain that might influence sleep EEG (43). The role played 
by cortico-cortical connections of the dmPFC will be an important subject for future study.   
 
Relationship between sleep and depression 
An essential question in investigating the relationship between sleep disturbances and depression 
is whether one precedes the other (either in sequence or cause and effect), or they occur 
simultaneously (due to a common underlying biology). The presence of abnormal sleep patterns 
in depressed patients is well established, and there is evidence for causation in both directions.  
Animals that have been subjected to chronic mild stress demonstrate significantly 
fragmented sleep and increased REM sleep (24; 45), as do animals that have been exposed to 
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regular inescapable footshocks (46). Stress is also associated with sleep changes in humans such 
as reduced sleep efficiency, however these subjects display decreased REM sleep unlike 
depressed patients (47). On the other hand, there is evidence that sleep changes are associated 
with increased vulnerability to depression: for instance, a persistent short REM sleep latency 
appears to increase the risk of relapse (48). Furthermore, healthy, never-depressed subjects with 
a strong family history of depression display specific sleep markers including higher REM 
density and decreased slow-wave sleep in the first NREM episode (49). Interestingly, patients in 
remission also show these characteristics (50). These markers may therefore indicate 
vulnerability to developing depression. 
Several longitudinal studies confirm that poor sleep quality and decreased (or 
significantly increased) quantity increases the risk of developing an affective disorder (51–53), 
regardless of family history. In a European study, insomnia was found to precede MDD 
diagnosis in over 40% of initial episodes, and over 50% of relapses (54). Another group found 
that persistence of insomnia for one year increases the likelihood of becoming depressed by forty 
times (51). On the other hand, it is possible that in these studies the subjects have either 
preclinical depression or a pre-existing condition – for instance, persistent anxiety, a chronic 
medical condition etc. – that may give rise to depression, independent of its effect on sleep 
disturbances. Furthermore, as the diagnosis of depression is based on exhibiting a specific 
number of symptoms, and some of those are sleep symptoms, the existence of a sleep disorder 
may simply lower the threshold for other symptoms to meet the criteria for diagnosis.  If one 
considers thatsome mood-related symptoms are closely associated with changes in sleep (for 
example if insomnia causes daytime fatigue), the effect of sleep disorders on reducing the 
threshold for diagnosing depression is magnified.  
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Although our results in this study do not shed light on the question of cause and effect, 
they do point to an explanation for why affective disorders and REM sleep changes often occur 
simultaneously. The rat vmPFC, a key structure in integrating information from the limbic 
system, is also a modulator of the REM-sleep system in the brainstem. Therefore change in 
activity in this region (or its human homologue, the SGC) that occurs as a result of negative life 
events (5) may influence sleep, which may be a component of predisposing the individual to 
depression. 
 
Clinical Significance and Conclusion 
The correlation between REM latency and FST immobility is intriguing. In humans several 
studies have found that REM latency is closely correlated with the Hamilton Depression Score 
(55–58). One possible interpretation is that the same population of neurons in the deep layers of 
the vmPFC reduces REM sleep and depression. However, not all studies have affirmed this 
correlation and decreased REM latency appears to be found in other psychiatric diseases as well 
(59–61). Therefore, the neural mechanism underlying early entry into REM sleep needs to be 
determined. 
Our findings emphasize the importance of the vmPFC in modulating immobility in the 
FST, and reveal its role in modulating sleep. This structure is therefore a possible explanation for 
the sleep changes – increased fragmentation, increased REM sleep, and decreased REM latency 
– most frequently associated with major depressive disorder. This conjecture is strengthened by 
the knowledge that the prefrontal cortex of humans displays abnormal activity while in a 
depressed state. Although direction of causality between sleep and depression is still to be 
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determined, our study suggests that their neural circuitries overlap, yet may be distinct, as 
increases in REM sleep (without the other changes) are also observed in dmPFC lesions.  
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Chapter 4 
 
Conclusion 
 
 
In this work, I addressed two questions related to major depressive disorder: 1) what are the 
targets of antidepressant action? and 2) what role does the ventromedial prefrontal cortex play in 
the induction of depression-associated behaviors? In the second chapter, I injected desipramine, 
fluoxetine, or ketamine systemically into rats and observed areas of the brain that were activated 
by the drugs using cfos immunohistochemical labeling. I found that within the PFC, the deep 
layers of the ventromedial PFC were selectively activated by all three drugs, while the vmPFC 
superficial layers were no different from saline-injected controls. However, KET also activated 
the dorsal region of the mPFC, whereas DMI and FLX did not. I also found that the nucleus 
accumbens was activated by DMI, and that this activation was dependent on the vmPFC. In 
addition, about 13% of the cells in the vmPFC that project to the NAc expressed cfos following 
DMI treatment. In the third chapter, I lesioned animals in the ventral and dorsal mPFC of rats 
and observed their response to tests of depression-like behavior. I found that REM sleep was 
increased in both lesion groups, but only the vmPFC had the following additional depression-like 
behaviors: reduced REM sleep latency, increased sleep fragmentation and increased immobility 
in the forced swim test. Lastly, I used tracer injections to propose how the subregions of the 
mPFC may be modulating REM sleep. I found that the dmPFC and vmPFC both project to cells 
in the REM-off vlPAG that subsequently project to the REM-on SLD, suggesting a possible 
pathway of REM sleep modulation. Altogether, my results suggest that the vmPFC may be a 
	   131 
critical region for both the etiology of major depressive disorder and its treatment via 
antidepressant drugs. 
 
Antidepressant drugs and the ventromedial prefrontal cortex 
Cellular mechanisms of antidepressant action 
The result that DMI, FLX and KET selectively activate the deep layers of the vmPFC is 
intriguing because KET has a very distinct mechanism compared to the other two. The drugs 
may therefore share neural targets in bringing about their antidepressant effects on the depression 
circuitry. A current hypothesis of MDD is that it is a disease characterized by neuronal and glial 
atrophy, and antidepressants may work to increase cell growth and synaptic plasticity. For 
instance, chronic treatment of human glial cells with FLX or imipramine, a tricyclic 
antidepressant, led to increased levels of the sterol regulatory element-binding protein, which 
regulates cell lipogenesis and is important for cell growth (1). Mice that were administered 
chronic doses of FLX, DMI and the monoamine oxidase inhibitor tranylcypromine showed 
significantly increased levels of cAMP response element transcription (2), which is central to 
many cellular processes including growth. In addition, chronic FLX administration increased 
cellular proliferation in the rat PFC, as measured by mitotic cell counts (3). KET administration 
also leads to increased spine density in the PFC, and blocking a the mTOR cellular growth 
pathway via rapamycin prevented synaptogenesis and its ability to suppress immobility in the 
FST (4).  
A striking difference between the action of KET and the typical antidepressants is their 
timing. While DMI and FLX require a few weeks of chronic administration before patient mood 
is alleviated, KET can act within a day (5). This difference may be due to variability in the time 
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required to achieve neuroplasticity, for the experiments supporting the idea that traditional 
antidepressants may cause plasticity required chronic administration. My cfos experiments do 
not reveal clues about the timing of the drugs, so different experimental methods will be 
necessary to investigate this particular aspect. For example, it will be interesting to observe the 
effect of chronic DMI on regional brain activity. However, a challenge of this experiment is that 
rodents develop tolerances to cfos expression, meaning that neurons may express less and less 
cfos if they are repeatedly activated. Therefore, an alternate method (such as using a different 
immediate early gene, or measuring mRNA instead of protein expression) will be required. 
Administration of an NMDA receptor antagonist would be expected to result in decreased 
activation of its target cells. Therefore, it is surprising to observe that KET selectively activates 
areas of the rat brain at subanesthetic doses. One possible explanation is that the mPFC is 
normally inhibited by another neural locus, and KET acts to disinhibit the ventral and dorsal 
mPFC. Alternatively, KET may have a stronger affinity for the interneurons compared to 
pyramidal cells within the mPFC, and thus block the inhibiting effects of GABAergic 
interneurons on pyramidal cells. This explanation is supported by the finding that administration 
of MK801, another NMDA antagonist, into rats led to decreased firing of fast-spiking 
interneurons followed by increased pyramidal cell activity (6).  
 
Role of the nucleus accumbens in action of desipramine 
As mentioned, DMI also increased cfos expression in the NAc. This structure is believed to be 
important for both conditioned and unconditioned response to rewarding stimuli, and it has been 
proposed that dysfunction in this region may be responsible for anhedonia (7). I hypothesized 
that activation of the vmPFC leads to increased glutamatergic firing, and thus excitation of its 
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downstream targets. To determine whether this is true in the NAc, I administered DMI to 
vmPFCx animals and counted the cfos-labeled cells. The finding that the vmPFC lesions reduced 
the number of drug-activated cells in the NAc indicated that this may be an important pathway 
by which the drug acts on the limbic circuitry. However, additional studies need to be completed 
to elucidate the role of the NAc in antidepressant action. For instance, in a future study DMI can 
be administered during the forced swim test on animals with NAc neuronal lesions. This would 
demonstrate whether the NAc is essential for the effect DMI has on reducing FST immobility. 
Ideally, additional rodent tests for depression would be used, for it is possible that different 
aspects of depression are controlled by different neural circuitries. This is especially true since 
the NAc is reputed to play a role in anhedonia, so the sucrose preference test would be a good 
test for this aspect of depression.  
 
Sleep, depression and the vmPFC 
Circuitry of sleep changes in depression 
In Chapter 3, I lesioned the dorsal and ventral regions of the rat mPFC and investigated the 
animals’ sleep-wake behavior and immobility in the forced swim test. The finding that both 
dmPFCx and vmPFCx animals had increased REM sleep, while the vmPFCx animals had 
additional depression-like behavioral characteristics, suggests that the circuitry responsible for 
increased REM sleep may be distinct from that which is involved in REM latency and FST 
immobility. Injection of the retrograde tracer CTB into the vlPAG labels cells in both the dmPFC 
and vmPFC, so these cortical areas may suppress REM sleep via direct glutamatergic projection 
to the REM-off control area. Although I did not observe any other structures that potentially link 
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the REM-executive structures with the mPFC in my tracing studies, I cannot rule out the 
possibility that another pathway contributes to the mPFC-mediated REM sleep changes. 
The neural pathway that caused sleep fragmentation in vmPFCx remains to be elucidated. 
The vmPFC projects to the ventrolateral preoptic area, which is an important sleep-promoting 
structure in the brain. Loss of vmPFCàVLPO projections in vmPFCx animals may be 
disrupting the sleep-wake switch, leading to increased fragmentation. Although additional 
experiments need to be performed to test this hypothesis, it will be difficult to determine whether 
this specific projection is responsible for fragmentation. 
Spectral analysis of the EEG waveforms of dmPFCx and vmPFCx animals demonstrated 
that dmPFCx animals had a significantly different distribution of frequency bands compared to 
control animals during NREM sleep. That is, animals in this experimental group had 
proportionately greater delta waves and fewer high-frequency waves. This result is puzzling, and 
the implications of this distribution shift are unclear. The dorsal region of the mPFC has major 
projections to other neocortical regions, so loss of these projections may be affecting cortical 
EEG waveforms. 
 
Sleep as a marker or cause of depression 
In the past it has been suggested that shortened REM latency may be a marker for depression, for 
REM latency measures were found to be correlated with Hamilton Depression scores (8–10). In 
addition, REM latency was the sole sleep characteristic that displayed a relationship to 
depression severity and could be objectively measured (8). However, in the years following, the 
importance of REM latency in MDD was diminished because other psychiatric disorders – such 
as schizophrenia – were also found to be associated with REM latency decreases (11). My result 
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that REM latency and FST immobility are significantly negatively correlated appears to support 
the suggestion that REM latency may indeed have biological significance in affect. The face 
validity of FST immobility is a topic of debate, but if one assumes that it is a measure of 
depression-like behaviors and that immobility time may be correlated depression-like severity, 
then REM latency may be a marker of a specific dysfunction in the limbic system. 
The neuroanatomical basis of shortened REM latency in these animals is unclear. 
Reduced REM latency is presumably a result of weakening of the REM-off switch or 
strengthening of the REM-on switch during sleep. As there are many neural structures that 
influence the vlPAG and SLD (as mentioned in Chapter 1), the neural circuitry of shortened 
REM latency needs to be investigated in future animal studies. Although my proposed model for 
REM sleep regulation by the mPFC may also be a factor in REM latency modulation, my model 
proposes similar circuitries for the dorsal and ventral regions of the mPFC. However, since 
shortened REM latency is unique to vmPFC-lesioned animals, I predict that a separate circuitry 
(such as the vmPFC projection to the lateral hypothalamus) is responsible for REM latency 
changes. Furthermore, as suggested above, the negative correlation between REM latency and 
FST immobility is indicative of the involvement of the limbic system in this result. 
In general, my findings that lesions in the vmPFC cause increased REM sleep, decreased 
REM latency and increased immobility in the FST present a potential explanation for why sleep 
disturbances are closely linked to depression. The vmPFC in the rat, and its purported human 
homolog (BAs 25 and 32), may be a region of the brain where the limbic and sleep-modulating 
circuitries overlap. Therefore, dysfunction of this region may be related to the manifestation of 
all three behavioral outcomes. However, my findings do not address 1) what could be causing 
this dysfunction in depression and 2) whether sleep disturbances are a cause or effect of 
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depressed mood. Some published preclinical and clinical studies, as mentioned previously, 
suggest that persistent adverse conditions may lead to cellular changes in the PFC. For instance, 
chronic stress in rats leads to atrophy in the dendrites of cells in the mPFC (12; 13), and a 
postmortem study of depressed and healthy humans showed that the former had decreased glial 
densities and decreased neuron cell body sizes (14). Therefore it is possible that gray matter loss 
in the PFC of depressed patients (14–17) is a direct consequence of stress, anxiety, and other 
causes of persistent depressed mood. Therefore MDD, or its precursor, may be a disease of these 
cortical changes that could subsequently influence one’s sleep. 
However, there is also evidence that sleep changes are not directly caused by the cortical 
changes in MDD. Shortened REM latency and reduced sleep efficiency were found to remain in 
remitted subjects (18), despite it being reported elsewhere that remitted patients do not show 
gray matter volume differences compared to healthy controls (17). In addition, specific sleep 
characteristics – increased REM density (which has been reported in depressed patients) and 
decreased slow-wave sleep in the first NREM episode – were found to be present in healthy, 
never-depressed subjects with a strong family history of depression (19). Lastly, presence of 
insomnia for at least a year is a potent predictor of depression, suggesting that sleep disturbances 
may arise before the neurobiological changes that lead to MDD diagnosis (20).  
 
Clinical implications of rat vmPFC lesion results 
My results in Chapter 3 suggest that reduced activity in the rat vmPFC, and possibly human 
vmPFC, is associated with a number of characteristics of depression. This notion is supported by 
the findings that in MDD patients that were symptomatic at time of death, there is reduced 
expression of immediate early gene transcripts zif268 and arc in the ventral anterior cingulate 
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cortex (21). However, these results are confusing considering that the subgenual cingulate region 
is found to be overactive in depressed patients (22; 23) and decreases in activity when a patient 
clinically responds to antidepressant treatment (24; 25). There are a few possible explanations for 
these apparently conflicting results. As my rodent lesion study, the human postmortem study and 
the imaging studies did not differentiate cellular subtypes, the different methods may be 
detecting abnormal activity in different cell types or cortical layers. For example, in MDD there 
may be subpopulations of the ventral PFC that display significantly increased and decreased 
activity. Alternatively, these studies may be demonstrating that there is an optimal level of 
cellular activity in this region that lies on an inverted U-shape curve. As a result, both too much 
and too little activity may lead to dysfunction and depression-associated behaviors. Thirdly, 
increased activity in human imaging studies may be compensatory, due to decreased neuronal 
body sizes and glial numbers in the ventral PFC (14). Lastly, a result of abnormal function in 
another structure in the depression circuitry may lead to disinhibition or hyperactivation of the 
ventral PFC. Further study in both humans and animals are required to unveil additional details 
in characterizing this region as it relates to depression. 
 
Conclusion 
In depressed patients, the prefrontal cortex displays abnormalities in metabolic activity, blood 
flow, and gray matter volume. There is evidence that some of these changes are reversed upon 
successful antidepressant therapy. I was motivated by these findings to investigate the 
importance of the prefrontal cortex in antidepressant action and the manifestation of depression. 
In my animal studies, I found that the ventromedial prefrontal cortex is a common target of three 
different drugs with antidepressant effects, in contrast to other regions of the cortex and brain. In 
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addition, lesions of this area give rise to depression-like behaviors in sleep and the forced swim 
test. Together, these results emphasize the importance of the rat vmPFC in modeling depression 
and antidepressants. However, the neural circuitry of each of these outcomes still needs to be 
investigated in detail to gain a better understanding of the vmPFC as a participant within the 
limbic network. For instance, it will be important to characterize the types of cells in the vmPFC 
that are activated by each drug to gain a deeper understanding of the local and downstream 
effects of their increased activation. As traditional antidepressants require chronic use for a few 
weeks before its effects are developed, the cellular events that occur during the transition from 
acute to chronic drug administration need to be elucidated. In addition, my hypothesis that PFC 
alterations in MDD may be related to the characteristic REM sleep changes observed in 
depressed patients needs to be tested in a clinical setting. These and future studies will be 
important for developing more effective antidepressant and possibly preventative measures for 
the disease that is predicted to soon become the greatest cause of health burden around the globe.  
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